OK
Oklahoma House Bill HB2584

Oklahoma 2025 Regular Session

Oklahoma House Bill HB2584 Compare Versions

OldNewDifferences
11
22
3-SENATE FLOOR VERSION - HB2584 SFLR Page 1
4-(Bold face denotes Committee Amendments) 1
5-2
6-3
7-4
8-5
9-6
10-7
11-8
12-9
13-10
14-11
15-12
16-13
17-14
18-15
19-16
20-17
21-18
22-19
23-20
24-21
25-22
26-23
27-24
28-
29-SENATE FLOOR VERSION
30-April 21, 2025
31-AS AMENDED
3+ENGR. H. B. NO. 2584 Page 1 1
4+2
5+3
6+4
7+5
8+6
9+7
10+8
11+9
12+10
13+11
14+12
15+13
16+14
17+15
18+16
19+17
20+18
21+19
22+20
23+21
24+22
25+23
26+24
3227
3328 ENGROSSED HOUSE
3429 BILL NO. 2584 By: Hilbert of the House
3530
3631 and
3732
3833 Paxton of the Senate
3934
4035
4136
4237
4338 An Act relating to physician assistants; amending 59
44-O.S. 2021, Section 353.1, as amended by Section 6,
45-Chapter 288, O.S.L. 2022 (59 O.S. Supp. 2024, Section
46-353.1), which relates to definitions used in the
47-Oklahoma Pharmacy Act; modifying definitions;
48-amending 59 O.S. 2021, Section 353.1a, which relates
49-to the Oklahoma Pharmacy Act; clarifying which
50-prescriptions for co ntrolled dangerous substances
51-pharmacists may dispense; amending 59 O.S. 2021,
52-Sections 519.2, 519.3, 519.6, and 519.11, as amended
53-by Section 1, Chapter 164, O.S.L. 2022 (59 O.S. Supp.
54-2024, Section 519.11), which relate to the Physician
55-Assistant Act; modifying definitions; increasing the
56-number of Physician Assistant Committee members;
57-clarifying certain requirements for the chair;
58-increasing member requirements for a quorum; adding
59-provisions regarding postgraduate clinical practice;
60-clarifying filing requirements for practice
61-agreements; clarifying language regarding practicing
62-medicine, prescribing drugs, and using medical
63-supplies under a practice agreement; modifying
64-billing and payment authority; prescribing certain
65-malpractice insurance requirement s; amending 63 O.S.
66-2021, Section 1-317, as last amended by Section 133,
67-Chapter 452, O.S.L. 2024 (63 O.S. Supp. 2024, Section
68-1-317), which relates to the Oklahoma Public Health
69-Code; clarifying the authority of physician
70-assistants to carry out certain f unctions; amending
71-63 O.S. 2021, Sections 2 -101, as last amended by
72-Section 1, Chapter 308, O.S.L. 2024, and 2 -312, as
73-amended by Section 2 , Chapter 184, O.S.L. 2022 (63
74-O.S. Supp. 2024, Sections 2 -101 and 2-312), which
75-relate to the Uniform Controlled Dan gerous Substances
76-
77-SENATE FLOOR VERSION - HB2584 SFLR Page 2
78-(Bold face denotes Committee Amendments) 1
79-2
80-3
81-4
82-5
83-6
84-7
85-8
86-9
87-10
88-11
89-12
90-13
91-14
92-15
93-16
94-17
95-18
96-19
97-20
98-21
99-22
100-23
101-24
102-
103-Act; modifying definitions related to physician
39+O.S. 2021, Section 353.1a, which relates to the
40+Oklahoma Pharmacy Act; clarifying which prescriptions
41+for controlled dangerous substances pharmacists may
42+dispense; amending 59 O.S. 2021, Sections 519.2,
43+519.3, 519.6, and 519.11, as amended by Section 1,
44+Chapter 164, O.S.L. 2022 (59 O.S. Supp. 2024, Section
45+519.11), which relate to the Physician Assistant Act;
46+modifying definitions; increasing the number of
47+Physician Assistant Committee members; clarifying
48+certain requirements for the chair; increasing member
49+requirements for a quorum; adding provisions
50+regarding postgraduate clinical practice; clarifying
51+filing requirements for practice agreements;
52+clarifying language regarding practicing medicine,
53+prescribing drugs, and using medical supplies under a
54+practice agreement; modifying billing and payment
55+authority; amending 63 O.S. 2021, Section 1 -317, as
56+last amended by Section 133, Chapter 452, O.S.L. 2024
57+(63 O.S. Supp. 2024, Section 1 -317), which relates to
58+the Oklahoma Public Health Code; clarifying the
59+authority of physician assistants to carry out
60+certain functions; amending 63 O.S. 2021, Sections 2 -
61+101, as last amended by Section 1, Chapter 308,
62+O.S.L. 2024, and 2-312, as amended by Section 2,
63+Chapter 184, O.S.L. 2022 (63 O.S. Supp. 2024,
64+Sections 2-101 and 2-312), which relate to the
65+Uniform Controlled Dangerous Substances Act;
66+modifying definitions related to phy sician
10467 assistants; clarifying which physician assistants may
10568 prescribe and administer certai n controlled
10669 substances; and repealing 59 O.S. 2021, Section
10770 521.4, which relates to physician supervision and
10871 practice agreements.
10972
11073
11174
11275
76+ENGR. H. B. NO. 2584 Page 2 1
77+2
78+3
79+4
80+5
81+6
82+7
83+8
84+9
85+10
86+11
87+12
88+13
89+14
90+15
91+16
92+17
93+18
94+19
95+20
96+21
97+22
98+23
99+24
100+
113101 BE IT ENACTED BY THE PEOPLE O F THE STATE OF OKLAHOMA:
114-SECTION 1. AMENDATORY 59 O.S. 2021, Section 353.1, as
115-amended by Section 6, Chapter 288, O.S.L. 2022 (59 O.S. Supp. 2024,
116-Section 353.1), is amen ded to read as follows:
117-Section 353.1. For the purposes of the Oklahoma Pharmacy Act:
118-1. “Accredited program” means those seminars, classes,
119-meetings, work projects, and other educational courses approved by
120-the Board State Board of Pharmacy for purposes of continuing
121-professional education;
122-2. “Act” means the Oklahoma Pharmacy Act;
123-3. “Administer” means the direct application of a drug, whether
124-by injection, inhalation, ingestion , or any other means, to the body
125-of a patient;
126-4. “Assistant pharmacist” means any person presently licensed
127-as an assistant pharmacist in the State of Oklahoma this state by
128-the Board pursuant to Section 353.10 of this title and for the
129-purposes of the Oklahoma Pharmacy Act shall be considered the same
130-as a pharmacist, except where otherwise specified ;
131-5. “Board” or “State Board” means the State Board of Pharmacy;
132-
133-SENATE FLOOR VERSION - HB2584 SFLR Page 3
134-(Bold face denotes Committee Amendments) 1
135-2
136-3
137-4
138-5
139-6
140-7
141-8
142-9
143-10
144-11
145-12
146-13
147-14
148-15
149-16
150-17
151-18
152-19
153-20
154-21
155-22
156-23
157-24
158-
159-6. “Certify” or “certification of a prescription” means the
160-review of a filled prescription by a licensed pharmacist or a
161-licensed practitioner with dispensing aut hority to confirm that the
162-medication, labeling , and packaging of the filled prescription are
163-accurate and meet all requirements prescribed by state and federal
164-law. For the purposes of this paragraph, “licensed practitioner”
165-shall not include optometrist s with dispensing authorit y;
166-7. “Chemical” means any medicinal substance, whether simple or
167-compound or obtained through the process of the science and art of
168-chemistry, whether of organic or inorganic origin;
169-8. “Compounding” means the combining, admixi ng, mixing,
170-diluting, pooling, reconstituting , or otherwise altering of a drug
171-or bulk drug substance to create a drug. Compounding includes the
172-preparation of drugs or devices in anticipation of prescription drug
173-orders based on routine, regularly observ ed prescribing patterns;
174-9. “Continuing professional education” means professional,
175-pharmaceutical education in the general areas of the socioeconomic
176-and legal aspects of health care; the properties and actions of
177-drugs and dosage forms; and the etiology , characteristics, and
178-therapeutics of the diseased state;
179-10. “Dangerous drug”, “legend drug”, “prescription drug”, or
180-“Rx Only” means a drug:
181-a. for human use subject to 21 U.S.C. , Section 353(b)(1),
182-or
183-
184-SENATE FLOOR VERSION - HB2584 SFLR Page 4
185-(Bold face denotes Committee Amendments) 1
186-2
187-3
188-4
189-5
190-6
191-7
192-8
193-9
194-10
195-11
196-12
197-13
198-14
199-15
200-16
201-17
202-18
203-19
204-20
205-21
206-22
207-23
208-24
209-
210-b. is labeled “Prescription Only”, or labeled with the
211-following statement: “Caution: Federal law restricts
212-this drug except for to use by or on the order of a
213-licensed veterinarian.”;
214-11. “Director” means the Executive Director of the State Board
215-of Pharmacy unless context clearly indicates otherwise;
216-12. “Dispense” or “dispensing” means the interpretation,
217-evaluation, and implementation of a prescription drug order
218-including the preparation and delivery of a drug or device to a
219-patient or a patient’s agent in a suitable container appropriately
220-labeled for subsequent administr ation to, or use by, a patient.
221-Dispense includes sell, distribute, leave with, give away, dispose
222-of, deliver, or supply;
223-13. “Dispenser” means a retail pharmacy, hospital pharmacy, a
224-group of chain pharmacies under common owne rship and control that do
225-not act as a wholesale distributor, or any other person authorized
226-by law to dispense or administer prescription drugs, and the
227-affiliated warehouses or distributions of such entities under common
228-ownership and control that do not act as a wholesale distri butor.
229-For the purposes of this paragraph, “dispenser” dispenser does not
230-mean a person who dispenses only products to be used in animals in
231-accordance with 21 U.S.C. , Section 360b(a)(5);
232-14. “Distribute” or “distribution” means the sale, purchase,
233-trade, delivery, handling, storage, or receipt of a product, and
234-
235-SENATE FLOOR VERSION - HB2584 SFLR Page 5
236-(Bold face denotes Committee Amendments) 1
237-2
238-3
239-4
240-5
241-6
242-7
243-8
244-9
245-10
246-11
247-12
248-13
249-14
250-15
251-16
252-17
253-18
254-19
255-20
256-21
257-22
258-23
259-24
260-
261-does not include the dispensing of a product pursuant to a
262-prescription executed in accordance with 21 U.S.C. , Section
263-353(b)(1) or the dispensing of a product approved u nder 21 U.S.C.,
264-Section 360b(b); provided, taking actual physical possession of a
265-product or title shall not be required;
266-15. “Doctor of Pharmacy” means a person licensed by the Board
267-to engage in the practice of pharmacy. The terms “pharmacist”,
268-“D.Ph.”, and “Doctor of Pharmacy” shall be interchangeable and shall
269-have the same meaning wherever they appear in the Oklahoma Statutes
270-and the rules promulgated by the Board;
271-16. “Drug outlet” means all manufacturers, repackagers,
272-outsourcing facilities, whole sale distributors, third -party
273-logistics providers, pharmacies, and all other facilities which are
274-engaged in dispensing, delivery, distribution , or storage of
275-dangerous drugs;
276-17. “Drugs” means all medicinal substances and preparations
277-recognized by the United States Pharmacopoeia Pharmacopeia and
278-National Formulary, or any revision thereof, and all substances and
279-preparations intended for external and/or internal use in the cure,
280-diagnosis, mitigation, treatment , or prevention of disease in humans
281-or animals and all substances an d preparations, other than food,
282-intended to affect the structure or any function of the body of a
283-human or animals;
284-
285-SENATE FLOOR VERSION - HB2584 SFLR Page 6
286-(Bold face denotes Committee Amendments) 1
287-2
288-3
289-4
290-5
291-6
292-7
293-8
294-9
295-10
296-11
297-12
298-13
299-14
300-15
301-16
302-17
303-18
304-19
305-20
306-21
307-22
308-23
309-24
310-
311-18. “Drug sample” means a unit of a prescription drug packaged
312-under the authority and responsibility of the man ufacturer that is
313-not intended to be sold and is intended to promote the sale of the
314-drug;
315-19. “Durable medical equipment” has the same meaning as
316-provided by Section 2 of this act Section 375.2 of this title ;
317-20. “Filled prescription” means a packaged prescription
318-medication to which a label has been affixed which contains such
319-information as is required by the Oklahoma Pharmacy Act;
320-21. “Hospital” means any institution licensed as a hospital by
321-this state for the care and treatment of patients, or a ph armacy
322-operated by the Oklahoma Department of Veterans Affairs;
323-22. “Licensed practitioner” means:
324-a. an allopathic physician,
325-b. an osteopathic physician,
326-c. a podiatric physician,
327-d. a dentist,
328-e. a veterinarian or,
329-f. an optometrist, or
330-g. a physician assistant,
331-licensed to practice and authorized to prescribe dangerous drugs
332-within the scope of practice of such practitioner;
333-23. “Manufacturer” or “virtual manufacturer” means with respect
334-to a product:
335-
336-SENATE FLOOR VERSION - HB2584 SFLR Page 7
337-(Bold face denotes Committee Amendments) 1
338-2
339-3
340-4
341-5
342-6
343-7
344-8
345-9
346-10
347-11
348-12
349-13
350-14
351-15
352-16
353-17
354-18
355-19
356-20
357-21
358-22
359-23
360-24
361-
362-a. a person that holds an application approved und er 21
363-U.S.C., Section 355 or a license issued under 42
364-U.S.C., Section 262 for such product, or if such
365-product is not the subject of an approved application
366-or license, the person who manufactured the product,
367-b. a co-licensed partner of the person descri bed in
368-subparagraph a of this paragraph that obtains the
369-product directly from a person described in this
370-subparagraph or subparagraph a of this paragraph,
371-c. an affiliate of a person described in subparagraph a
372-or b of this paragraph who receives the prod uct
373-directly from a person described in this subparagraph
374-or in subparagraph a or b of this paragraph, or
375-d. a person who contracts with another to manufacture a
376-product;
377-24. “Manufacturing” means the production, preparation,
378-propagation, compounding, con version, or processing of a device or a
379-drug, either directly or indirectly by extraction from substances of
380-natural origin or independently by means of chemical or biological
381-synthesis and includes any packaging or repackaging of the
382-substances or labelin g or relabeling of its container, and the
383-promotion and marketing of such drugs or devices. The term
384-“manufacturing” manufacturing also includes the preparation and
385-promotion of commercially available products from bulk compounds for
386-
387-SENATE FLOOR VERSION - HB2584 SFLR Page 8
388-(Bold face denotes Committee Amendments) 1
389-2
390-3
391-4
392-5
393-6
394-7
395-8
396-9
397-10
398-11
399-12
400-13
401-14
402-15
403-16
404-17
405-18
406-19
407-20
408-21
409-22
410-23
411-24
412-
413-resale by licensed ph armacies, licensed practit ioners, or other
414-persons;
415-25. “Medical gas” means those gases including those in liquid
416-state upon which the manufacturer or distributor has placed one of
417-several cautions, such as “Rx Only”, in compliance with federal law;
418-26. “Medical gas order” means an order for medical gas issued
419-by a licensed prescriber;
420-27. “Medical gas distributor” means a person licensed to
421-distribute, transfer, wholesale, deliver , or sell medical gases on
422-drug orders to suppliers or other entities lice nsed to use,
423-administer, or distribute medical gas and may also include a patient
424-or ultimate user;
425-28. “Medical gas supplier” means a person who dispenses medical
426-gases on drug orders only to a patient or ultimate user;
427-29. “Medicine” means any drug or combination of drugs which has
428-the property of curing, preventing, treating, diagnosing , or
429-mitigating diseases, or which is used for that purpose;
430-30. “Nonprescription drugs” means medicines or drugs which are
431-sold without a prescription and which are pr epackaged for use by the
432-consumer and labeled in accordance with the requirements of the
433-statutes and regulations of this state and the federal government.
434-Such items shall also include medical and dental supplies and
435-bottled or nonbulk chemicals which ar e sold or offered for sale to
436-the general public if such articles or preparations meet the
437-
438-SENATE FLOOR VERSION - HB2584 SFLR Page 9
439-(Bold face denotes Committee Amendments) 1
440-2
441-3
442-4
443-5
444-6
445-7
446-8
447-9
448-10
449-11
450-12
451-13
452-14
453-15
454-16
455-17
456-18
457-19
458-20
459-21
460-22
461-23
462-24
463-
464-requirements of the Federal Food, Drug , and Cosmetic Act, 21
465-U.S.C.A., Section 321 et seq.;
466-31. “Outsourcing facility” including “virtual outsourcing
467-facility” means a facility at one geogra phic location or address
468-that:
469-a. is engaged in the compounding of sterile drugs,
470-b. has elected to register as an outsourcing facility,
471-and
472-c. complies with all requirements of 21 U.S.C. , Section
473-353b;
474-32. “Package” means the sm allest individual saleable unit of
475-product for distribution by a manufacturer or repackager that is
476-intended by the manufacturer for ultimate sale to the dispenser of
477-such product. For the purposes of this paragraph, “individual
478-saleable unit” means the s mallest container of a pro duct introduced
479-into commerce by the manufacturer or repackager that is intended by
480-the manufacturer or repackager for individual sale to a dispenser;
481-33. “Person” means an individual, partnership, limited
482-liability company, corp oration, or association, unless the context
483-otherwise requires;
484-34. “Pharmacist-in-charge” or “PIC” means the pharmacist
485-licensed in this state responsible for the management control of a
486-pharmacy and all other aspects of the practice of pharmacy in a
487-
488-SENATE FLOOR VERSION - HB2584 SFLR Page 10
489-(Bold face denotes Committee Amendments) 1
490-2
491-3
492-4
493-5
494-6
495-7
496-8
497-9
498-10
499-11
500-12
501-13
502-14
503-15
504-16
505-17
506-18
507-19
508-20
509-21
510-22
511-23
512-24
513-
514-licensed pharmacy as defined provided by Section 353.18 of this
515-title;
516-35. “Pharmacy” means a place regularly licensed by the State
517-Board of Pharmacy in which prescriptions, drugs, medicines,
518-chemicals, and poisons are compounded or dispensed or such place
519-where pharmacists practice the profession of pharmacy, or a pharmacy
520-operated by the Oklahoma Department of Veterans Affairs;
521-36. “Pharmacy technician”, “technician”, “Rx tech”, or “tech”
522-means a person issued a Technician technician permit by the State
523-Board of Pharmacy to assist the pharmacist and perform
524-nonjudgmental, technical, manipulative, non -discretionary functions
525-in the prescription department under the immediate and direct
526-supervision of a pharmacist;
527-37. “Poison” means any substance which when introduced into the
528-body, either directly or by absorption, produces violent, morbid , or
529-fatal changes, or which destroys living tissue with which such
530-substance comes into contact;
531-38. “Practice of pharmacy” means:
532-a. the interpretation and evaluation o f prescription
533-orders,
534-b. the compounding, dispensing, administering , and
535-labeling of drugs and devices, except labeling by a
536-manufacturer, repackager , or distributor of
537-
538-SENATE FLOOR VERSION - HB2584 SFLR Page 11
539-(Bold face denotes Committee Amendments) 1
540-2
541-3
542-4
543-5
544-6
545-7
546-8
547-9
548-10
549-11
550-12
551-13
552-14
553-15
554-16
555-17
556-18
557-19
558-20
559-21
560-22
561-23
562-24
563-
564-nonprescription drugs and commercially packaged legend
565-drugs and devices,
566-c. the participation in drug selection and drug
567-utilization reviews,
568-d. the proper and safe storage of drugs and devices and
569-the maintenance of proper records thereof,
570-e. the responsibility for advising by counseling and
571-providing information, where professionally nec essary
572-or where regulated, of therapeutic values, content,
573-hazards, and use of drugs and devices,
574-f. the offering or performing of those acts, services,
575-operations, or transactions necessary in the conduct,
576-operation, management , and control of a pharmacy, or
577-g. the provision of those acts or services that are
578-necessary to provide pharmaceutical care;
579-39. “Preparation” means an article which may or may not contain
580-sterile products compounded in a licensed pharmacy pursuant to the
581-order of a licensed prescr iber;
582-40. “Prescriber” me ans a person licensed in this state who is
583-authorized to prescribe dangerous drugs within the scope of practice
584-of the person’s profession;
585-41. “Prescription” means and includes any order for drug or
586-medical supplies written or s igned, or transmitted by word of mouth,
587-telephone, or other means of communication:
588-
589-SENATE FLOOR VERSION - HB2584 SFLR Page 12
590-(Bold face denotes Committee Amendments) 1
591-2
592-3
593-4
594-5
595-6
596-7
597-8
598-9
599-10
600-11
601-12
602-13
603-14
604-15
605-16
606-17
607-18
608-19
609-20
610-21
611-22
612-23
613-24
614-
615-a. by a licensed prescriber,
616-b. (1) under the supervision of an Oklahoma licensed
617-practitioner a supervising physician , by an Oklahoma
618-licensed advanced practice registered nurse, or
619-(2) by an Oklahoma licensed physician assistant
620-pursuant to a practice agreement , or
621-c. by an Oklahoma licensed wholesaler or distributor as
622-authorized in Section 353.29.1 of this title;
623-42. “Product” means a prescription drug in a finished dos age
624-form for administration to a patient without substantial further
625-manufacturing, such as capsules, tablets, and lyophilized products
626-before reconstitution. “Product” Product does not include blood
627-components intended for transfusion, radioactive drugs or biologics
628-and medical gas;
629-43. “Repackager”, including “virtual repackager”, means a
630-person who owns or operates an establishment that repacks and
631-relabels a product or package for further sale or distribution
632-without further transaction;
633-44. “Sterile drug” means a drug that is intended for parenteral
634-administration, an ophthalmic or oral inhalation drug in aqueous
635-format, or a drug that is required to be sterile under state and
636-federal law;
637-45. “Supervising physician” means an individual holding a
638-current license to practice as a physician from the State Board of
639-
640-SENATE FLOOR VERSION - HB2584 SFLR Page 13
641-(Bold face denotes Committee Amendments) 1
642-2
643-3
644-4
645-5
646-6
647-7
648-8
649-9
650-10
651-11
652-12
653-13
654-14
655-15
656-16
657-17
658-18
659-19
660-20
661-21
662-22
663-23
664-24
665-
666-Medical Licensure and Supervision, pursuant to the provisions of the
667-Oklahoma Allopathic Medical and Surgical Licensure and Supervision
668-Act, or the State Board of Osteopathic Examiners, pursu ant to the
669-provisions of the Oklahoma Osteopathic Medicine Act, who supervises
670-an advanced practice registered nurse as defined in Section 567.3a
671-of this title,
672-and who is not in training as an intern, resident, or fellow. To be
673-eligible to supervise an a dvanced practice registere d nurse, such
674-physician shall remain in compliance with the rules promulgated by
675-the State Board of Medical Licensure and Supervision or the State
676-Board of Osteopathic Examiners;
677-46. “Supportive personnel” means technicians and a uxiliary
678-supportive persons who are regularly paid employees of a pharmacy
679-who work and perform tasks in the pharmacy as authorized by Section
680-353.18A of this title;
681-47. “Third-party logistics provider” including “virtual third -
682-party logistics provider” m eans an entity that provid es or
683-coordinates warehousing, or other logistics services of a product in
684-interstate commerce on behalf of a manufacturer, wholesale
685-distributor, or dispenser of a product but does not take ownership
686-of the product, nor have resp onsibility to direct the sale or
687-disposition of the product. For the purposes of this paragraph,
688-“third-party logistics provider” third-party logistics provider does
689-not include shippers and the United States Postal Service;
690-
691-SENATE FLOOR VERSION - HB2584 SFLR Page 14
692-(Bold face denotes Committee Amendments) 1
693-2
694-3
695-4
696-5
697-6
698-7
699-8
700-9
701-10
702-11
703-12
704-13
705-14
706-15
707-16
708-17
709-18
710-19
711-20
712-21
713-22
714-23
715-24
716-
717-48. “Wholesale distributor” i ncluding “virtual wholesal e
718-distributor” means a person other than a manufacturer, a
719-manufacturer’s co-licensed partner, a third -party logistics
720-provider, or repackager engaged in wholesale distribution as defined
721-by 21 U.S.C., Section 353(e)(4) as amended by the Drug Supply Chain
722-Security Act;
723-49. “County jail” means a facility operated by a county for the
724-physical detention and correction of persons charged with, or
725-convicted of, criminal offenses or ordinance violations or persons
726-found guilty of civil or criminal contempt;
727-50. “State correctional facility” means a facility or
728-institution that houses a prisoner population under the jurisdiction
729-of the Department of Corrections;
730-51. “Unit dose package” means a package that contains a single
731-dose drug with the name, strength, control number, and expiration
732-date of that drug on the label; and
733-52. “Unit of issue package” means a package that provides
734-multiple doses of the same drug, but each drug is individually
735-separated and includes the name, lot number, and expiration date.
736-SECTION 2. AMENDATORY 59 O.S. 2021, Section 353.1a, is
102+SECTION 1. AMENDATORY 59 O.S. 2021, Section 353.1a, is
737103 amended to read as follows:
738104 Section 353.1a A. Prescribing authority shall be allowed,
739105 under the medical direction of a supervising physician, for an
740106 advanced practice nurse recognized by the Oklahoma Board of Nursing
741-
742-SENATE FLOOR VERSION - HB2584 SFLR Page 15
743-(Bold face denotes Committee Amendments) 1
744-2
745-3
746-4
747-5
748-6
749-7
750-8
751-9
752-10
753-11
754-12
755-13
756-14
757-15
758-16
759-17
760-18
761-19
762-20
763-21
764-22
765-23
766-24
767-
768107 in one of the following categories: advanced registered nurse
769108 practitioners, clinical nurse specialists, or certified nurse -
770109 midwives. The advanced pract ice nurse may write or sign, or
771110 transmit by word of mouth, telephone or other means of communication
772111 an order for drugs or medical supplies that is intended to be
773112 filled, compounded, or dispensed by a pharmacist. The supervising
774113 physician and the advanced practice nurse shall be identifi ed at the
775114 time of origination of the prescription and the name of the advanced
776115 practice nurse shall be printed on the prescription label.
777116 B. Pharmacists may dispense prescriptions for non -controlled
778117 prescription drugs auth orized by an advanced practice nu rse or
779118 physician assistant, not located in Oklahoma, provided that they are
780119 licensed in the state in which they are actively prescribing.
781120 C. Pharmacists may only dispense prescriptions for controlled
782121 dangerous substances prescribed by an:
783122 1. An advanced practice nurse or physician assistant licensed
784123 in the State of Oklahoma and supervised by an Oklahoma -licensed
785124 practitioner; or
125+
126+ENGR. H. B. NO. 2584 Page 3 1
127+2
128+3
129+4
130+5
131+6
132+7
133+8
134+9
135+10
136+11
137+12
138+13
139+14
140+15
141+16
142+17
143+18
144+19
145+20
146+21
147+22
148+23
149+24
150+
786151 2. A physician assistant licensed in the State of Oklahoma and
787152 supervised by an Oklahoma -licensed practitioner.
788-SECTION 3. AMENDATORY 59 O.S. 2021, Section 519.2, is
153+SECTION 2. AMENDATORY 59 O.S. 2021, Section 519.2, is
789154 amended to read as follows:
790155 Section 519.2 As used in the Physician Assistant Act:
791-
792-SENATE FLOOR VERSION - HB2584 SFLR Page 16
793-(Bold face denotes Committee Amendments) 1
794-2
795-3
796-4
797-5
798-6
799-7
800-8
801-9
802-10
803-11
804-12
805-13
806-14
807-15
808-16
809-17
810-18
811-19
812-20
813-21
814-22
815-23
816-24
817-
818156 1. "Board" means the State Board of Medical Licensure and
819157 Supervision;
820158 2. "Committee" means the Physician Assistant Committee;
821159 3. "Practice of medicine" means services which require training
822160 in the diagnosis, treatment and prevention of disease, including the
823161 use and administration of drugs, and which are performed by
824162 physician assistants so long as such serv ices are within the
825163 physician assistants' skill ,. For a physician assistant required to
826164 practice under supervision of a delegating physician, services form
827165 a component of the physician's scope of practice, and are provided
828166 with physician supervision, incl uding authenticating by signature
829167 any form that may be authenticated by the delegating physician's
830168 signature with prior delegation by the physician;
831169 4. "Patient care setting" means and includes, but is not
832170 limited to, a physician's office, clinic, hospita l, nursing home,
833171 extended care facility, patient's home, ambulatory surgical center,
834172 hospice facility or any other setting authorized by the delegating
835173 physician;
174+
175+ENGR. H. B. NO. 2584 Page 4 1
176+2
177+3
178+4
179+5
180+6
181+7
182+8
183+9
184+10
185+11
186+12
187+13
188+14
189+15
190+16
191+17
192+18
193+19
194+20
195+21
196+22
197+23
198+24
199+
836200 5. "Physician assistant" means a health care professional,
837201 qualified by academic and clinica l education and licensed by the
838202 State Board of Medical Licensure and Supervision, to practice
839203 medicine with physician supervision as a physician assistant ;
840204 6. 5. "Delegating physician" means an individual holding a
841205 license in good standing as a physician from the State Board of
842-
843-SENATE FLOOR VERSION - HB2584 SFLR Page 17
844-(Bold face denotes Committee Amendments) 1
845-2
846-3
847-4
848-5
849-6
850-7
851-8
852-9
853-10
854-11
855-12
856-13
857-14
858-15
859-16
860-17
861-18
862-19
863-20
864-21
865-22
866-23
867-24
868-
869206 Medical Licensure and Supervision or the State Board of Osteopathic
870207 Examiners, who supervises one or more physician assistants and
871208 delegates decision making pursuant to the practice agreement;
872209 7. 6. "Supervision" means overseeing o r delegating the
873210 activities of the medical services rendered by a physician assistant
874211 through a practice agreement between a medical doctor or osteopathic
875212 delegating physician performing procedures or directly or indirectly
876213 involved with the treatment of a patient, and the physician
877214 assistant working jointly toward a common goal of providing
878215 services. Delegation shall be defined by the practice agreement .
879216 The physical presence of the delegating physician is not required as
880217 long as the delegating physician and physician assistant are or can
881218 be easily in contact with each other by telecommunication. At all
882219 times a physician assistant required to practice under supervision
883220 shall be considered an agent of the delegating physic ian;
884221 8. 7. "Telecommunication" m eans the use of electronic
885222 technologies to transmit words, sounds or images for interpersonal
223+
224+ENGR. H. B. NO. 2584 Page 5 1
225+2
226+3
227+4
228+5
229+6
230+7
231+8
232+9
233+10
234+11
235+12
236+13
237+14
238+15
239+16
240+17
241+18
242+19
243+20
244+21
245+22
246+23
247+24
248+
886249 communication, clinical care (telemedicine) and review of electronic
887250 health records; and
888251 9. 8. "Practice agreement" means a written agreement between a
889252 physician assistant and the a delegating physician concerning the
890253 scope of practice of the physician assistant to only be determined
891254 by the delegating physician and the physician assistant based on the
892255 education, training, skills an d experience of the physician
893-
894-SENATE FLOOR VERSION - HB2584 SFLR Page 18
895-(Bold face denotes Committee Amendments) 1
896-2
897-3
898-4
899-5
900-6
901-7
902-8
903-9
904-10
905-11
906-12
907-13
908-14
909-15
910-16
911-17
912-18
913-19
914-20
915-21
916-22
917-23
918-24
919-
920256 assistant. The agreement shall involve the joint formulation,
921257 discussion and agreement on the methods of supervision and
922258 collaboration for diagnosis, consultation and treatment of medical
923259 conditions and shall include the scope of and any limitations on
924260 prescribing. A practice agreement is required for a physician
925261 assistant as described in subsection C of Section 519.6 of this
926262 title.
927-SECTION 4. AMENDATORY 59 O.S. 2021, Section 519.3, is
263+SECTION 3. AMENDATORY 59 O.S. 2021, Section 519.3, is
928264 amended to read as follows:
929265 Section 519.3 A. There is hereby created the Physician
930266 Assistant Committee, which shall be composed of seven (7) nine (9)
931267 members. Three Five members of the Committee shall be physician
932268 assistants appointed by the State Board of Medical Licensure and
933269 Supervision from a li st of qualified individuals submitted by the
934270 Oklahoma Academy of Physician Assistants. One member shall be a
935271 physician appointed by the Board from its membership. One member
936272 shall be a physician appointed by the Board fro m a list of qualified
273+
274+ENGR. H. B. NO. 2584 Page 6 1
275+2
276+3
277+4
278+5
279+6
280+7
281+8
282+9
283+10
284+11
285+12
286+13
287+14
288+15
289+16
290+17
291+18
292+19
293+20
294+21
295+22
296+23
297+24
298+
937299 individuals submitted by the Oklahoma State Medical Association and
938300 who is not a member of the Board. One member shall be a physician
939301 appointed by the State Board of Osteopathic Examiners from its
940302 membership. One member shall be a physician appointed by the State
941303 Board of Osteopathic Examiners from a list of qualified individuals
942304 submitted by the Oklahoma Osteopathic Association and who is not a
943305 member of said board.
944-
945-SENATE FLOOR VERSION - HB2584 SFLR Page 19
946-(Bold face denotes Committee Amendments) 1
947-2
948-3
949-4
950-5
951-6
952-7
953-8
954-9
955-10
956-11
957-12
958-13
959-14
960-15
961-16
962-17
963-18
964-19
965-20
966-21
967-22
968-23
969-24
970-
971306 B. The term of office for each member of the Committee shall be
972307 five (5) years.
973308 C. The Committee shall meet at least quarterly. At the initial
974309 meeting of each calendar year, the Committee members shall elect a
975310 chair from the physician assistant members . The chair or his or her
976311 designee shall represent the Committee at all meetings of the Board.
977312 Four Five members shall constitute a quorum for the purpose of
978313 conducting official business of the Committee.
979314 D. The State Board of Medical Licensure and Supervision is
980315 hereby granted the power and authority to promulgate rule s, which
981316 are in accordance with t he provisions of Section 519.1 et seq. of
982317 this title, governing the requirements for licensure as a physician
983318 assistant, as well as to establish standards for training, approve
984319 institutions for training, and regulate the standards of practice of
985320 a physician assistant after licensure, including the power of
986321 revocation of a license.
322+
323+ENGR. H. B. NO. 2584 Page 7 1
324+2
325+3
326+4
327+5
328+6
329+7
330+8
331+9
332+10
333+11
334+12
335+13
336+14
337+15
338+16
339+17
340+18
341+19
342+20
343+21
344+22
345+23
346+24
347+
987348 E. The State Board of Medical Licensure and Supervision is
988349 hereby granted the power and authority to investigate all
989350 complaints, hold hearings, s ubpoena witnesses and initiate
990351 prosecution concerning violations of Section 519.1 et seq. of this
991352 title. When such complaints involve physicians licensed by the
992353 State Board of Osteopathic Examiners, the State Board of Osteopathic
993354 Examiners shall be officially notified of such complaints.
994-
995-SENATE FLOOR VERSION - HB2584 SFLR Page 20
996-(Bold face denotes Committee Amendments) 1
997-2
998-3
999-4
1000-5
1001-6
1002-7
1003-8
1004-9
1005-10
1006-11
1007-12
1008-13
1009-14
1010-15
1011-16
1012-17
1013-18
1014-19
1015-20
1016-21
1017-22
1018-23
1019-24
1020-
1021355 F. 1. The Committee shall advise the Board on all matters
1022356 pertaining to the practice of physician assistants.
1023357 2. The Committee shall review and make recommendations to the
1024358 Board on all applications for licensure as a ph ysician assistant and
1025359 all applications to practice which shall be approved by the Board.
1026360 When considering applicants for licensure, to establish standards of
1027361 training or approve institutions for training, the Committee shall
1028362 include the Director, or designee, of all Physician Assistant
1029363 educational programs conducted by institutions of higher education
1030364 in the state as members.
1031365 3. The Committee shall assist and advise the Board in all
1032366 hearings involving physician assistants who are deemed to be in
1033367 violation of Section 519.1 et seq. of this title or the rules of the
1034368 Board.
1035-SECTION 5. AMENDATORY 59 O.S. 2021, Section 519.6, is
369+SECTION 4. AMENDATORY 59 O.S. 2021, Section 519.6, is
1036370 amended to read as follows:
371+
372+ENGR. H. B. NO. 2584 Page 8 1
373+2
374+3
375+4
376+5
377+6
378+7
379+8
380+9
381+10
382+11
383+12
384+13
385+14
386+15
387+16
388+17
389+18
390+19
391+20
392+21
393+22
394+23
395+24
396+
1037397 Section 519.6 A. No health care services may be performed by a
1038398 physician assistant unless a current license is o n file with and
1039399 approved by the State Board of Medical Licensure and Supervision.
1040400 B. A physician assistant with six thousand two hundred forty
1041401 (6,240) or more hours of postgraduate clinical practice experience
1042402 who has reported those hours to the Board sha ll not be required to
1043403 practice under the supervision of a delegating physician.
1044-
1045-SENATE FLOOR VERSION - HB2584 SFLR Page 21
1046-(Bold face denotes Committee Amendments) 1
1047-2
1048-3
1049-4
1050-5
1051-6
1052-7
1053-8
1054-9
1055-10
1056-11
1057-12
1058-13
1059-14
1060-15
1061-16
1062-17
1063-18
1064-19
1065-20
1066-21
1067-22
1068-23
1069-24
1070-
1071404 1. A physician assistant may report the completion of
1072405 postgraduate clinical practice experience to the Board at any time
1073406 after completion of at least six thousand two hundred forty (6,240)
1074407 such hours.
1075408 2. Hours earned prior to the enactment of this subsection shall
1076409 be counted towards the six thousand two hundred forty (6,240) hours.
1077410 3. The Board shall maintain, make available, and keep updated,
1078411 on the Internet website of the B oard, a list of physician assistants
1079412 who have reported completion of six thousand two hundred forty
1080413 (6,240) or more postgraduate clinical practice experience hours.
1081-4. The Board shall prescribe a form for reporting postgraduate
1082-clinical practice experience b y a physician assistant. The Board
1083-shall make available and keep updated on the Internet website of the
1084-Board the prescribed form. This reporting form may be filed
1085-electronically. The Board shall not charge a fee for reporting
1086-hours or filing of the pre scribed form.
414+4. The Board shall, within ninety (90) days of enactment,
415+prescribe a form for reporting p ostgraduate clinical practice
416+experience by a physician assistant. The Board shall make available
417+and keep updated on the Internet website of the Board the prescribed
418+form. This reporting form may be filed electronically. The Board
419+shall not charge a fe e for reporting hours or filing of the
420+prescribed form.
421+
422+ENGR. H. B. NO. 2584 Page 9 1
423+2
424+3
425+4
426+5
427+6
428+7
429+8
430+9
431+10
432+11
433+12
434+13
435+14
436+15
437+16
438+17
439+18
440+19
441+20
442+21
443+22
444+23
445+24
446+
1087447 5. Nothing in this subsection shall prohibit a physician
1088448 assistant from maintaining a practice agreement; however, such an
1089449 agreement is not required for a physician assistant with the
1090450 reported six thousand two hundred forty (6,240) hours of
1091451 postgraduate clinical practice experience, provided any practice
1092452 agreements are subject to the requirements of paragraphs 1, 2, 3,
1093453 and 4 of subsection C of this section.
1094-
1095-SENATE FLOOR VERSION - HB2584 SFLR Page 22
1096-(Bold face denotes Committee Amendments) 1
1097-2
1098-3
1099-4
1100-5
1101-6
1102-7
1103-8
1104-9
1105-10
1106-11
1107-12
1108-13
1109-14
1110-15
1111-16
1112-17
1113-18
1114-19
1115-20
1116-21
1117-22
1118-23
1119-24
1120-
1121454 6. Nothing in this subsection shall restric t the ability of the
1122455 Board to require supervision as a part of disciplinary action
1123456 against the license of a physician assistant.
1124457 C. A physician assistant with less than six thousand two
1125458 hundred forty (6,240) hours of postgraduate clinical practice
1126459 experience or who has completed six thousand two hundred forty
1127460 (6,240) hours but has not reported those hours to the Board shall
1128461 practice under the supervision of a delegating physician with the
1129462 following requirements:
1130463 1. All practice agreements and any amendmen ts shall be filed
1131464 with the State Board of Medical Licensure and Supervision within ten
1132465 (10) business days of being executed. Practice agreements may be
1133466 filed electronically. The State Board of Medical Licensure and
1134467 Supervision shall not charge a fee for filing practice agreements or
1135468 amendments of to practice agreements.;
1136469 B. 2. A physician assistant may have practice agreements with
1137470 multiple allopathic or osteopathic physicians. Each physician shall
471+
472+ENGR. H. B. NO. 2584 Page 10 1
473+2
474+3
475+4
476+5
477+6
478+7
479+8
480+9
481+10
482+11
483+12
484+13
485+14
486+15
487+16
488+17
489+18
490+19
491+20
492+21
493+22
494+23
495+24
496+
1138497 be in good standing wi th the State Board of Medical Lic ensure and
1139498 Supervision or the State Board of Osteopathic Examiners .;
1140499 C. 3. The delegating physician need not be physically present
1141500 nor be specifically consulted before each delegated patient care
1142501 service is performed by a physician assistant, so long as t he
1143502 delegating physician and physician assistant are or can be easily in
1144503 contact with one another by means of telecommunication. In all
1145-
1146-SENATE FLOOR VERSION - HB2584 SFLR Page 23
1147-(Bold face denotes Committee Amendments) 1
1148-2
1149-3
1150-4
1151-5
1152-6
1153-7
1154-8
1155-9
1156-10
1157-11
1158-12
1159-13
1160-14
1161-15
1162-16
1163-17
1164-18
1165-19
1166-20
1167-21
1168-22
1169-23
1170-24
1171-
1172504 patient care settings, the The delegating physician shall provide
1173505 appropriate methods o f participating in health care se rvices
1174506 provided by the physician assistant including:
1175507 a. being responsible for the formulation or approval of
1176508 all orders and protocols, whether standing orders,
1177509 direct orders or any other orders or protocols, which
1178510 direct the delivery of health care servic es provided
1179511 by a physician assistant, and periodically reviewing
1180512 such orders and protocols,
1181513 b. regularly reviewing the health care services provided
1182514 by the physician assistant and any problems or
1183515 complications encountered,
1184516 c. being available physically or through telemedicine or
1185517 direct telecommunications for consultation, assistance
1186518 with medical emergencies or patient referral,
1187519 d. reviewing a sample of outpatient medical records.
1188520 Such reviews shall take place at a site agreed upon
521+
522+ENGR. H. B. NO. 2584 Page 11 1
523+2
524+3
525+4
526+5
527+6
528+7
529+8
530+9
531+10
532+11
533+12
534+13
535+14
536+15
537+16
538+17
539+18
540+19
541+20
542+21
543+22
544+23
545+24
546+
1189547 between the delegating ph ysician and physician
1190548 assistant in the practice agreement which may also
1191549 occur using electronic or virtual conferencing, and
1192550 e. that it remains clear that the physician assistant is
1193551 an agent of the delegating physician; but , in no event
1194552 shall the delegating physician be an employee of the
1195553 physician assistant.;
1196-
1197-SENATE FLOOR VERSION - HB2584 SFLR Page 24
1198-(Bold face denotes Committee Amendments) 1
1199-2
1200-3
1201-4
1202-5
1203-6
1204-7
1205-8
1206-9
1207-10
1208-11
1209-12
1210-13
1211-14
1212-15
1213-16
1214-17
1215-18
1216-19
1217-20
1218-21
1219-22
1220-23
1221-24
1222-
1223554 D. 4. In patients with newly diagnosed complex illnesses, the
1224555 physician assistant shall contact the delegating physician within
1225556 forty-eight (48) hours of the physician assistant's initial
1226557 examination or treatment and schedule the patient for appropriate
1227558 evaluation by the delegating physician as directed by the physician.
1228559 The delegating physician shall determine which conditions qualify as
1229560 complex illnesses based on th e clinical setting and the skill and
1230561 experience of the physician assistant.
1231562 E. 1. D. A physician assistant under the direction of a
1232563 delegating physician not practicing under a practice agreement may
1233564 prescribe written and oral prescriptions and orders. The physician
1234565 assistant not practicing under a practice agreement may prescribe
1235566 medical supplies, services, and drugs, including controlled
1236567 medications in Schedules II III through V pursuant to Section 2 -312
1237568 of Title 63 of the Oklahoma Statutes , and medical supplies and
1238569 services as delegated by the delegating physician and as approved by
1239570 the State Board of Medical Licensure and Supervision after
571+
572+ENGR. H. B. NO. 2584 Page 12 1
573+2
574+3
575+4
576+5
577+6
578+7
579+8
580+9
581+10
582+11
583+12
584+13
585+14
586+15
587+16
588+17
589+18
590+19
591+20
592+21
593+22
594+23
595+24
596+
1240597 consultation with the State Board of Pharmacy on the Physician
1241598 Assistant Drug Formulary . Physician assistants not practicing under
1242599 a practice agreement may not dispense drugs, but may request,
1243600 receive, and sign for professional samples and may distribute
1244601 professional samples to patients.
1245602 2. A physician assistant may write an order for a Schedule II
1246603 drug for immediate or ongoing administration on si te. Prescriptions
1247-
1248-SENATE FLOOR VERSION - HB2584 SFLR Page 25
1249-(Bold face denotes Committee Amendments) 1
1250-2
1251-3
1252-4
1253-5
1254-6
1255-7
1256-8
1257-9
1258-10
1259-11
1260-12
1261-13
1262-14
1263-15
1264-16
1265-17
1266-18
1267-19
1268-20
1269-21
1270-22
1271-23
1272-24
1273-
1274604 and orders for Schedule II drugs written by a physician assistant
1275605 must be included on a written protocol determined by the delegating
1276606 physician and approved by the medical staff committee of the
1277607 facility or by direct verbal order of the delegating physician.
1278608 Physician assistants may not dispense drugs, but may request,
1279609 receive, and sign for professional samples and may distribute
1280610 professional samples to patients.
1281611 F. E. A physician assistant may perform health care services in
1282612 patient care settings as authorized by the delegating physician
1283613 practicing under a practice agreement may prescribe written and oral
1284614 prescriptions and orders. The physician assistant practicing under
1285615 a practice agreement may prescribe medical supplies, services, an d
1286616 drugs, including controlled medications in Schedules II through V
1287617 pursuant to Section 2 -312 of Title 63 of the Oklahoma Statutes,
1288618 written and oral prescriptions and orders only as delegated by the
1289619 delegating physician, an d prescriptions and orders for Sc hedule II
1290620 drugs written by such physician assistant shall be included on a
621+
622+ENGR. H. B. NO. 2584 Page 13 1
623+2
624+3
625+4
626+5
627+6
628+7
629+8
630+9
631+10
632+11
633+12
634+13
635+14
636+15
637+16
638+17
639+18
640+19
641+20
642+21
643+22
644+23
645+24
646+
1291647 written protocol determined by the delegating physician. Physician
1292648 assistants practicing under a practice agreement may not dispense
1293649 drugs, but may request, receive, and sign for p rofessional samples
1294650 and may distribute professional samples to patients. Provided that
1295651 a physician assistant practicing under a practice agreement may not
1296652 prescribe any controlled medications in a Schedule that the
1297653 delegating physician is not registered t o prescribe.
1298-
1299-SENATE FLOOR VERSION - HB2584 SFLR Page 26
1300-(Bold face denotes Committee Amendments) 1
1301-2
1302-3
1303-4
1304-5
1305-6
1306-7
1307-8
1308-9
1309-10
1310-11
1311-12
1312-13
1313-14
1314-15
1315-16
1316-17
1317-18
1318-19
1319-20
1320-21
1321-22
1322-23
1323-24
1324-
1325654 G. F. Each physician assistant licensed under the Physician
1326655 Assistant Act shall keep his or her license available for inspection
1327656 at the primary place of business and shall, when engaged in
1328657 professional activities, identify himself or herself as a physician
1329658 assistant.
1330659 H. G. A physician assistant shall be bound by the provisions
1331660 contained in Sections 725.1 through 725.5 of Title 59 of the
1332661 Oklahoma Statutes this title.
1333-H. 1. A physician assistant, or the employer of the physician
1334-assistant on his or her behalf, shall carry malpractice insurance or
1335-demonstrate proof of financial responsibility in a minimum amount of
1336-One Million Dollars ($1,000,000.00) per occurrence and Three Million
1337-Dollars ($3,000,000.00) in the aggregate per year. This requirement
1338-shall apply only to the physician a ssistant and shall not be
1339-construed as to require the physician assistant to provide
1340-malpractice insurance coverage to any delegating physician.
1341-2. A physician assistant who is employed by or under contract
1342-with a federal agency that carries malpractice i nsurance in any
1343-amount on behalf of the physician assistant shall be deemed in
1344-compliance with paragraph 1 of this subsection when practicing under
1345-such federal employment or contract. However, to the extent the
1346-physician assistant practices outside of su ch federal employment or
1347-contract, the physician assistant, or his or her employer, shall
1348-comply with paragraph 1 of this subsection.
1349-
1350-SENATE FLOOR VERSION - HB2584 SFLR Page 27
1351-(Bold face denotes Committee Amendments) 1
1352-2
1353-3
1354-4
1355-5
1356-6
1357-7
1358-8
1359-9
1360-10
1361-11
1362-12
1363-13
1364-14
1365-15
1366-16
1367-17
1368-18
1369-19
1370-20
1371-21
1372-22
1373-23
1374-24
1375-
1376-SECTION 6. AMENDATORY 59 O.S. 2021, Section 519.11, as
662+SECTION 5. AMENDATORY 59 O.S. 2021, Section 519.11, as
1377663 amended by Section 1, Chapter 164, O.S.L. 2022 (59 O.S. Supp. 2024,
1378664 Section 519.11), is amended to read as follows:
1379665 Section 519.11 A. Nothing in the Physician Assistant Act shall
1380666 be construed to prevent or restrict the practice, services or
1381667 activities of any persons of other licensed professions or personnel
1382668 supervised by licensed professions in this state from performing
1383669 work incidental to the practice of their profession or occupation,
670+
671+ENGR. H. B. NO. 2584 Page 14 1
672+2
673+3
674+4
675+5
676+6
677+7
678+8
679+9
680+10
681+11
682+12
683+13
684+14
685+15
686+16
687+17
688+18
689+19
690+20
691+21
692+22
693+23
694+24
695+
1384696 if that person does not represe nt himself or herself as a physician
1385697 assistant.
1386698 B. Nothing stated in the Physician Assistant Act shall prevent
1387699 any hospital from requiring the physician assistant or the
1388700 delegating physician to meet and maintain certain staff appointment
1389701 and credentialing qualifications for the privilege of practicing as,
1390702 or utilizing, a physician assistant in the hospital.
1391703 C. Nothing in the Physician Assistant Act shall be construed to
1392704 permit a physician assistant to practice medicine or prescribe drugs
1393705 and medical supplies in this state except when suc h actions are
1394706 performed under the supervision and at the direction of a physician
1395707 or physicians approved by the State Board of Medical Licensure and
1396708 Supervision.
1397709 D. Nothing herein shall be construed to require licensure under
1398710 the Physician Assistant Act o f a physician assistant student
1399711 enrolled in a physician assistant educational program accredited by
1400-
1401-SENATE FLOOR VERSION - HB2584 SFLR Page 28
1402-(Bold face denotes Committee Amendments) 1
1403-2
1404-3
1405-4
1406-5
1407-6
1408-7
1409-8
1410-9
1411-10
1412-11
1413-12
1414-13
1415-14
1416-15
1417-16
1418-17
1419-18
1420-19
1421-20
1422-21
1423-22
1424-23
1425-24
1426-
1427712 the Accreditation Review Commission on Education for the Physician
1428713 Assistant.
1429714 E. D. Notwithstanding any other provision of law, no one who is
1430715 not a physician licensed to practice medicine in this state may
1431716 perform acts restricted to such physicians pursuant to the
1432717 provisions of Section 1 -731 of Title 63 of the Oklahoma Statutes.
1433718 This paragraph subsection is inseverable.
719+
720+ENGR. H. B. NO. 2584 Page 15 1
721+2
722+3
723+4
724+5
725+6
726+7
727+8
728+9
729+10
730+11
731+12
732+13
733+14
734+15
735+16
736+17
737+18
738+19
739+20
740+21
741+22
742+23
743+24
744+
1434745 F. E. Nothing in the Physician Assis tant Act shall limit the
1435746 activities of a physician assistant in the performance of their
1436747 duties if the physician assistant is employed by or under contract
1437748 with the United States Department of Veterans Affairs or if the
1438749 physician assistant is employed by, under contract with, or
1439750 commissioned by one of the uniformed services; provided, the
1440751 physician assistant must be currently licensed in this state or any
1441752 other state or currently credentialed as a physician assistant by
1442753 the United States Department of Veter ans Affairs or the applicable
1443754 uniformed service. Any physician assistant who is employed by or
1444755 under contract with the United States Department of Veterans Affairs
1445756 or is employed by, under contract with, or commissioned by one of
1446757 the uniformed services an d practices outside of such employment,
1447758 contract, or commission shall be subject to the Physician Assistant
1448759 Act while practicing outside of such employment, contract, or
1449760 commission. As used in this subsection, "uniformed services" shall
1450-
1451-SENATE FLOOR VERSION - HB2584 SFLR Page 29
1452-(Bold face denotes Committee Amendments) 1
1453-2
1454-3
1455-4
1456-5
1457-6
1458-7
1459-8
1460-9
1461-10
1462-11
1463-12
1464-13
1465-14
1466-15
1467-16
1468-17
1469-18
1470-19
1471-20
1472-21
1473-22
1474-23
1475-24
1476-
1477761 have the same meaning as provided by Title 10 of the U.S. United
1478762 States Code.
1479-SECTION 7. AMENDATORY 63 O.S. 2021, Section 1 -317v2, as
763+SECTION 6. AMENDATORY 63 O.S. 2021, Section 1 -317v2, as
1480764 last amended by Section 133, Chapter 452, O.S.L. 2024 (63 O.S. Supp.
1481765 2024, Section 1-317v2), is amended to read as follows:
1482766 Section 1-317v2. A. A death certificate for each death which
1483767 occurs in this state shall be filed with the State Department of
1484768 Health, within three (3) days after such death.
769+
770+ENGR. H. B. NO. 2584 Page 16 1
771+2
772+3
773+4
774+5
775+6
776+7
777+8
778+9
779+10
780+11
781+12
782+13
783+14
784+15
785+16
786+17
787+18
788+19
789+20
790+21
791+22
792+23
793+24
794+
1485795 B. The funeral director shall personally sign the death
1486796 certificate and shall be responsible for filing the death
1487797 certificate. If the funeral director is not available, the person
1488798 acting as such who first assumes custody of a dead body in
1489799 accordance with Section 1158 of Title 21 of the Okla homa Statutes
1490800 shall personally sign and file the death certificate. The personal
1491801 data shall be obtained from the next of kin or the best qualified
1492802 person or source available. The funeral director or person acting
1493803 as such shall notify the person providing the personal data that it
1494804 is a felony to knowingly provide false data or misrepresent any
1495805 person’s relationship to the decedent. The certificate shall be
1496806 completed as to personal data and delivered to the attending
1497807 physician or the medical examiner respo nsible for completing the
1498808 medical certification portion of the certificate of death within
1499809 twenty-four (24) hours after the death. No later than July 1, 2012,
1500810 the personal data, and no later than July 1, 2017, the medical
1501-
1502-SENATE FLOOR VERSION - HB2584 SFLR Page 30
1503-(Bold face denotes Committee Amendments) 1
1504-2
1505-3
1506-4
1507-5
1508-6
1509-7
1510-8
1511-9
1512-10
1513-11
1514-12
1515-13
1516-14
1517-15
1518-16
1519-17
1520-18
1521-19
1522-20
1523-21
1524-22
1525-23
1526-24
1527-
1528811 certificate portion, shall be entered into the prescribed electron ic
1529812 system provided by the State Registrar of Vital Statistics and the
1530813 information submitted to the State Registrar of Vital Statistics.
1531814 The resultant certificate produced by the electronic system shall be
1532815 provided to the physician or medical examiner for medical
1533816 certification within twenty -four (24) hours after the death.
1534817 C. The medical certification shall be completed and signed
1535818 within forty-eight (48) hours after death by the physician,
819+
820+ENGR. H. B. NO. 2584 Page 17 1
821+2
822+3
823+4
824+5
825+6
826+7
827+8
828+9
829+10
830+11
831+12
832+13
833+14
834+15
835+16
836+17
837+18
838+19
839+20
840+21
841+22
842+23
843+24
844+
1536845 physician assistant, or advanced practice registered nurse in charg e
1537846 of the patient’s care for the illness or condition which resulted in
1538847 death, except when inquiry as to the cause of death is required by
1539848 Section 938 of this title. No later than July 1, 2017, the medical
1540849 certification portion of certificate data shall be entered into the
1541850 prescribed electronic system provided by the State Registrar of
1542851 Vital Statistics and the information submitted to the State
1543852 Registrar of Vital Statistics.
1544853 D. In the event that the physician, physician assistant, or
1545854 advanced practice regi stered nurse in charge of the patient’s care
1546855 for the illness or condition which resulted in death is not in
1547856 attendance at the time of death, the medical certification shall be
1548857 completed and signed within forty -eight (48) hours after death by
1549858 the physician, physician assistant, or advanced practice registered
1550859 nurse in attendance at the time of death, except:
1551-
1552-SENATE FLOOR VERSION - HB2584 SFLR Page 31
1553-(Bold face denotes Committee Amendments) 1
1554-2
1555-3
1556-4
1557-5
1558-6
1559-7
1560-8
1561-9
1562-10
1563-11
1564-12
1565-13
1566-14
1567-15
1568-16
1569-17
1570-18
1571-19
1572-20
1573-21
1574-22
1575-23
1576-24
1577-
1578860 1. When the patient is under hospice care at the time of death,
1579861 the medical certification may be signed by the hospice’s medical
1580862 director; and
1581863 2. When inquiry as to the cause of death is required by Section
1582864 938 of this title.
1583865 Provided, that such certification, if signed by other than the
1584866 attending physician, physician assistant, or advanced practice
1585867 registered nurse, sha ll note on the face the name of t he attending
868+
869+ENGR. H. B. NO. 2584 Page 18 1
870+2
871+3
872+4
873+5
874+6
875+7
876+8
877+9
878+10
879+11
880+12
881+13
882+14
883+15
884+16
885+17
886+18
887+19
888+20
889+21
890+22
891+23
892+24
893+
1586894 physician, physician assistant, or advanced practice registered
1587895 nurse and that the information shown is only as reported.
1588896 E. A certifier completing cause of death on a certificate of
1589897 death who knows that a lethal drug, overdose or other means of
1590898 assisting suicide within the meaning of Sections 3141.2 through
1591899 3141.4 of this title caused or contributed to the death shall list
1592900 that means among the chain of events under cause of death or list it
1593901 in the box that describes how the injury occurred. If such means is
1594902 in the chain of events under cause of death or in the box that
1595903 describes how the injury occurred, the certifier shall indicate
1596904 “suicide” as the manner of death.
1597905 F. The authority of a physician assistant subject to subsection
1598906 C of Section 519.6 of Title 59 of the Oklahoma Statutes to carry out
1599907 the functions described in this section shall be governed by the
1600908 practice agreement as provided by Section 519.6 of Title 59 of the
1601909 Oklahoma Statutes.
1602-
1603-SENATE FLOOR VERSION - HB2584 SFLR Page 32
1604-(Bold face denotes Committee Amendments) 1
1605-2
1606-3
1607-4
1608-5
1609-6
1610-7
1611-8
1612-9
1613-10
1614-11
1615-12
1616-13
1617-14
1618-15
1619-16
1620-17
1621-18
1622-19
1623-20
1624-21
1625-22
1626-23
1627-24
1628-
1629-SECTION 8. AMENDATORY 63 O.S. 2021, Section 2 -101, as
910+SECTION 7. AMENDATORY 6 3 O.S. 2021, Section 2 -101, as
1630911 last amended by Section 1, Chapter 308, O.S.L. 2024 (63 O.S. Supp.
1631912 2024, Section 2-101), is amended to read as follows:
1632913 Section 2-101. As used in the Uniform Controlled Dangerous
1633914 Substances Act:
1634915 1. “Acute pain” means pain, whether resulting from disease,
1635916 accidental trauma, intentional trauma, or other cause that the
1636917 practitioner reasonably expects to last only a short period of time.
918+
919+ENGR. H. B. NO. 2584 Page 19 1
920+2
921+3
922+4
923+5
924+6
925+7
926+8
927+9
928+10
929+11
930+12
931+13
932+14
933+15
934+16
935+17
936+18
937+19
938+20
939+21
940+22
941+23
942+24
943+
1637944 Acute pain does not include chronic pain, pain being treat ed as part
1638945 of cancer care, hospic e or other end-of-life care, or pain being
1639946 treated as part of palliative care;
1640947 2. “Administer” means the direct application of a controlled
1641948 dangerous substance, whether by injection, inhalation, ingestion or
1642949 any other means, to the body of a patient, anim al or research
1643950 subject by:
1644951 a. a practitioner (or, in the presence of the
1645952 practitioner, by the authorized agent of the
1646953 practitioner), or
1647954 b. the patient or research subject at the direction and
1648955 in the presence of the practiti oner;
1649956 3. “Agent” means a peace o fficer appointed by and who acts on
1650957 behalf of the Director of the Oklahoma State Bureau of Narcotics and
1651958 Dangerous Drugs Control or an authorized person who acts on behalf
1652959 of or at the direction of a person who manufactures, distributes,
1653-
1654-SENATE FLOOR VERSION - HB2584 SFLR Page 33
1655-(Bold face denotes Committee Amendments) 1
1656-2
1657-3
1658-4
1659-5
1660-6
1661-7
1662-8
1663-9
1664-10
1665-11
1666-12
1667-13
1668-14
1669-15
1670-16
1671-17
1672-18
1673-19
1674-20
1675-21
1676-22
1677-23
1678-24
1679-
1680960 dispenses, prescribes, administers or uses for scientific purposes
1681961 controlled dangerous substances but does not include a common or
1682962 contract carrier, public warehouser or employee thereof, or a person
1683963 required to register under the Uniform C ontrolled Dangerous
1684964 Substances Act;
1685965 4. “Anhydrous ammonia” means any substance that exhibits
1686966 cryogenic evaporative behavior and tests positive for ammonia;
967+
968+ENGR. H. B. NO. 2584 Page 20 1
969+2
970+3
971+4
972+5
973+6
974+7
975+8
976+9
977+10
978+11
979+12
980+13
981+14
982+15
983+16
984+17
985+18
986+19
987+20
988+21
989+22
990+23
991+24
992+
1687993 5. “Board” means the Advisory Board to the Director of the
1688994 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
1689995 6. “Bureau” means the Oklahoma State Bureau of Narcotics and
1690996 Dangerous Drugs Control;
1691997 7. “Chronic pain” means pain that persists beyond the usual
1692998 course of an acute disease or healing of an injury. Chronic pain
1693999 may or may not be associated with an acute or chro nic pathologic
16941000 process that causes continuous or intermittent pain over months or
16951001 years;
16961002 8. “Coca leaves” includes cocaine and any compound,
16971003 manufacture, salt, derivative, mixture or preparation of coca
16981004 leaves, except derivatives of coca leaves which do n ot contain
16991005 cocaine or ecgonine;
17001006 9. “Commissioner” or “Director” means the Director of the
17011007 Oklahoma State Bureau of Narcotics and Dangerous Drugs Control;
1702-
1703-SENATE FLOOR VERSION - HB2584 SFLR Page 34
1704-(Bold face denotes Committee Amendments) 1
1705-2
1706-3
1707-4
1708-5
1709-6
1710-7
1711-8
1712-9
1713-10
1714-11
1715-12
1716-13
1717-14
1718-15
1719-16
1720-17
1721-18
1722-19
1723-20
1724-21
1725-22
1726-23
1727-24
1728-
17291008 10. “Control” means to add, remove or change the placement of a
17301009 drug, substance or immediate precur sor under the Uniform Controlled
17311010 Dangerous Substances Act;
17321011 11. “Controlled dangerous substance” means a drug, substance or
17331012 immediate precursor in Schedules I through V of the Uniform
17341013 Controlled Dangerous Substances Act or any drug, substance or
17351014 immediate precursor listed either temporarily or permanently as a
17361015 federally controlled substance. Any conflict between state and
1016+
1017+ENGR. H. B. NO. 2584 Page 21 1
1018+2
1019+3
1020+4
1021+5
1022+6
1023+7
1024+8
1025+9
1026+10
1027+11
1028+12
1029+13
1030+14
1031+15
1032+16
1033+17
1034+18
1035+19
1036+20
1037+21
1038+22
1039+23
1040+24
1041+
17371042 federal law with regard to the particular schedule in which a
17381043 substance is listed shall be resolved in favor of state law;
17391044 12. “Counterfeit substance” means a controlled substance which,
17401045 or the container or labeling of which without authorization, bears
17411046 the trademark, trade name or other identifying marks, imprint,
17421047 number or device or any likeness thereof of a manufacturer,
17431048 distributor or dispenser other than the person who in fact
17441049 manufactured, distributed or dispensed the substance;
17451050 13. “Deliver” or “delivery” means the actual, constructive or
17461051 attempted transfer from one person to another of a controlled
17471052 dangerous substance or drug para phernalia, whether or not there is
17481053 an agency relationship;
17491054 14. “Dispense” means to deliver a controlled dangerous
17501055 substance to an ultimate user or human research subject by or
17511056 pursuant to the lawful order of a practitioner, including the
17521057 prescribing, administering, packaging, labeling or compounding
1753-
1754-SENATE FLOOR VERSION - HB2584 SFLR Page 35
1755-(Bold face denotes Committee Amendments) 1
1756-2
1757-3
1758-4
1759-5
1760-6
1761-7
1762-8
1763-9
1764-10
1765-11
1766-12
1767-13
1768-14
1769-15
1770-16
1771-17
1772-18
1773-19
1774-20
1775-21
1776-22
1777-23
1778-24
1779-
17801058 necessary to prepare the substance for such distribution.
17811059 “Dispenser” is a practitioner who delivers a controlled dangerous
17821060 substance to an ultimate user or human research subj ect;
17831061 15. “Distribute” means to d eliver other than by administering
17841062 or dispensing a controlled dangerous substance;
17851063 16. “Distributor” means a commercial entity engaged in the
17861064 distribution or reverse distribution of narcotics and dangerous
17871065 drugs and who complies with all regulations promu lgated by the
1066+
1067+ENGR. H. B. NO. 2584 Page 22 1
1068+2
1069+3
1070+4
1071+5
1072+6
1073+7
1074+8
1075+9
1076+10
1077+11
1078+12
1079+13
1080+14
1081+15
1082+16
1083+17
1084+18
1085+19
1086+20
1087+21
1088+22
1089+23
1090+24
1091+
17881092 federal Drug Enforcement Administration and the Oklahoma State
17891093 Bureau of Narcotics and Dangerous Drugs Control;
17901094 17. “Drug” means articles:
17911095 a. recognized in the official United States Pharmacopeia,
17921096 official Homeopathic Pharmacopoeia of the Un ited
17931097 States, or official National Formulary, or any
17941098 supplement to any of them,
17951099 b. intended for use in the diagnosis, cure, mitigation,
17961100 treatment or prevention of disease in man or other
17971101 animals,
17981102 c. other than food, intended to affect the structure or
17991103 any function of the body of man or other animals, and
18001104 d. intended for use as a component of any article
18011105 specified in this paragraph;
18021106 provided, however, the term drug does not include devices or their
18031107 components, parts or accesso ries;
1804-
1805-SENATE FLOOR VERSION - HB2584 SFLR Page 36
1806-(Bold face denotes Committee Amendments) 1
1807-2
1808-3
1809-4
1810-5
1811-6
1812-7
1813-8
1814-9
1815-10
1816-11
1817-12
1818-13
1819-14
1820-15
1821-16
1822-17
1823-18
1824-19
1825-20
1826-21
1827-22
1828-23
1829-24
1830-
18311108 18. “Drug paraphernalia” m eans all equipment, products, and
18321109 materials of any kind which are used, intended for use, or fashioned
18331110 specifically for use in planting, propagating, cultivating, growing,
18341111 harvesting, manufacturing, compounding, converting, producing,
18351112 processing, preparing , testing, analyzing, packaging, repackaging,
18361113 storing, containing, concealing, injecting, ingesting, inhaling, or
18371114 otherwise introducing into the human body, a controlled dangerous
1115+
1116+ENGR. H. B. NO. 2584 Page 23 1
1117+2
1118+3
1119+4
1120+5
1121+6
1122+7
1123+8
1124+9
1125+10
1126+11
1127+12
1128+13
1129+14
1130+15
1131+16
1132+17
1133+18
1134+19
1135+20
1136+21
1137+22
1138+23
1139+24
1140+
18381141 substance in violation of the Uniform Contr olled Dangerous
18391142 Substances Act including, but not limited to:
18401143 a. kits used, intended for use, or fashioned specifically
18411144 for use in planting, propagating, cultivating,
18421145 growing, or harvesting of any species of plant which
18431146 is a controlled dangerous substance or from which a
18441147 controlled dangerous substance can be derived,
18451148 b. kits used, intended for use, or fashioned specifically
18461149 for use in manufacturing, compounding, converting,
18471150 producing, processing, or preparing controlled
18481151 dangerous substances,
18491152 c. isomerization devices used, intended for use, or
18501153 fashioned specifically for use in increasing the
18511154 potency of any species of plant which is a controlled
18521155 dangerous substance,
18531156 d. testing equipment used, intended for use, or fashioned
18541157 specifically for use in identifying or in analyzing
1855-
1856-SENATE FLOOR VERSION - HB2584 SFLR Page 37
1857-(Bold face denotes Committee Amendments) 1
1858-2
1859-3
1860-4
1861-5
1862-6
1863-7
1864-8
1865-9
1866-10
1867-11
1868-12
1869-13
1870-14
1871-15
1872-16
1873-17
1874-18
1875-19
1876-20
1877-21
1878-22
1879-23
1880-24
1881-
18821158 the strength, effectiveness, or purity of controlled
18831159 dangerous substances,
18841160 e. scales and balances used, intended for use, or
18851161 fashioned specifically for use in weighing or
18861162 measuring controlled dangerous substances,
18871163 f. diluents and adulterants , such as quinine
18881164 hydrochloride, mannitol, mannite, dextrose, and
1165+
1166+ENGR. H. B. NO. 2584 Page 24 1
1167+2
1168+3
1169+4
1170+5
1171+6
1172+7
1173+8
1174+9
1175+10
1176+11
1177+12
1178+13
1179+14
1180+15
1181+16
1182+17
1183+18
1184+19
1185+20
1186+21
1187+22
1188+23
1189+24
1190+
18891191 lactose used, intended for use, or fashioned
18901192 specifically for use in cutting controlled dangerous
18911193 substances,
18921194 g. separation gins and sifters used, intended for use, or
18931195 fashioned specifically for use in removing twigs and
18941196 seeds from, or in otherwise cleaning or refining,
18951197 marijuana,
18961198 h. blenders, bowls, containers, spoons, and mixing
18971199 devices used, intended for use, or fashioned
18981200 specifically for use in compounding controlled
18991201 dangerous substances,
19001202 i. capsules, balloons, envelopes , and other containers
19011203 used, intended for use, or fashioned specifically for
19021204 use in packaging small quantities of controlled
19031205 dangerous substances,
19041206 j. containers and other objects used, intended for use,
19051207 or fashioned specifically for use in parenterally
1906-
1907-SENATE FLOOR VERSION - HB2584 SFLR Page 38
1908-(Bold face denotes Committee Amendments) 1
1909-2
1910-3
1911-4
1912-5
1913-6
1914-7
1915-8
1916-9
1917-10
1918-11
1919-12
1920-13
1921-14
1922-15
1923-16
1924-17
1925-18
1926-19
1927-20
1928-21
1929-22
1930-23
1931-24
1932-
19331208 injecting controlled dangerous substances into the
19341209 human body,
19351210 k. hypodermic syringes, needles, and other objects used,
19361211 intended for use, or fashioned specifically for use in
19371212 parenterally injecting controlled dangerous substan ces
19381213 into the human body, except a s authorized by Section
19391214 2-1101 of this title,
1215+
1216+ENGR. H. B. NO. 2584 Page 25 1
1217+2
1218+3
1219+4
1220+5
1221+6
1222+7
1223+8
1224+9
1225+10
1226+11
1227+12
1228+13
1229+14
1230+15
1231+16
1232+17
1233+18
1234+19
1235+20
1236+21
1237+22
1238+23
1239+24
1240+
19401241 l. objects used, intended for use, or fashioned
19411242 specifically for use in ingesting, inhaling, or
19421243 otherwise introducing marijuana, cocaine, hashish, or
19431244 hashish oil into the human body, such as:
19441245 (1) metal, wooden, acrylic, glass, stone, plastic, or
19451246 ceramic pipes with or without screens, permanent
19461247 screens, hashish heads, or punctured metal bowls,
19471248 (2) water pipes,
19481249 (3) carburetion tubes and devices,
19491250 (4) smoking and carburetion masks,
19501251 (5) roach clips, meaning objects u sed to hold burning
19511252 material, such as a marijuana cigarette, that has
19521253 become too small or too short to be held in the
19531254 hand,
19541255 (6) miniature cocaine spoons and cocaine vials,
19551256 (7) chamber pipes,
19561257 (8) carburetor pipes,
1957-
1958-SENATE FLOOR VERSION - HB2584 SFLR Page 39
1959-(Bold face denotes Committee Amendments) 1
1960-2
1961-3
1962-4
1963-5
1964-6
1965-7
1966-8
1967-9
1968-10
1969-11
1970-12
1971-13
1972-14
1973-15
1974-16
1975-17
1976-18
1977-19
1978-20
1979-21
1980-22
1981-23
1982-24
1983-
19841258 (9) electric pipes,
19851259 (10) air-driven pipes,
19861260 (11) chillums,
19871261 (12) bongs, or
19881262 (13) ice pipes or chillers,
19891263 m. all hidden or novelty pipes, and
1264+
1265+ENGR. H. B. NO. 2584 Page 26 1
1266+2
1267+3
1268+4
1269+5
1270+6
1271+7
1272+8
1273+9
1274+10
1275+11
1276+12
1277+13
1278+14
1279+15
1280+16
1281+17
1282+18
1283+19
1284+20
1285+21
1286+22
1287+23
1288+24
1289+
19901290 n. any pipe that has a tobacco bowl or chamber of less
19911291 than one-half (1/2) inch in diameter in which there is
19921292 any detectable residue of any controlled dangerous
19931293 substance as defined in this section or any other
19941294 substances not legal for possession or use;
19951295 provided, however, the term drug paraphernalia shall not include
19961296 separation gins intended for use in preparing tea or spice, clamps
19971297 used for constructing electrica l equipment, water pipes designed for
19981298 ornamentation in which no detectable amount of an illegal substance
19991299 is found or pipes designed and used solely for smoking tobacco,
20001300 traditional pipes of an American Indian tribal religi ous ceremony,
20011301 antique pipes that are thirty (30) years of age or older, or drug
20021302 testing strips possessed by a person for purposes of determining the
20031303 presence of fentanyl or a fentanyl -related compound;
20041304 19. “Drug-dependent person” means a person who is using a
20051305 controlled dangerous substan ce and who is in a state of psychic or
20061306 physical dependence, or both, arising from administration of that
20071307 controlled dangerous substance on a continuous basis. Drug
2008-
2009-SENATE FLOOR VERSION - HB2584 SFLR Page 40
2010-(Bold face denotes Committee Amendments) 1
2011-2
2012-3
2013-4
2014-5
2015-6
2016-7
2017-8
2018-9
2019-10
2020-11
2021-12
2022-13
2023-14
2024-15
2025-16
2026-17
2027-18
2028-19
2029-20
2030-21
2031-22
2032-23
2033-24
2034-
20351308 dependence is characterized by behavioral and other respon ses which
20361309 include a strong compul sion to take the substance on a continuous
20371310 basis in order to experience its psychic effects, or to avoid the
20381311 discomfort of its absence;
20391312 20. “Harm-reduction services” means programs established to:
1313+
1314+ENGR. H. B. NO. 2584 Page 27 1
1315+2
1316+3
1317+4
1318+5
1319+6
1320+7
1321+8
1322+9
1323+10
1324+11
1325+12
1326+13
1327+14
1328+15
1329+16
1330+17
1331+18
1332+19
1333+20
1334+21
1335+22
1336+23
1337+24
1338+
20401339 a. reduce the spread of infectious diseases related to
20411340 injection drug use,
20421341 b. reduce drug dependency, overdose deaths, and
20431342 associated complications, and
20441343 c. increase safe recovery and disposal of used syringes
20451344 and sharp waste;
20461345 21. “Hazardous materials” means materials, whether sol id,
20471346 liquid, or gas, which are tox ic to human, animal, aquatic, or plant
20481347 life, and the disposal of such materials is controlled by state or
20491348 federal guidelines;
20501349 22. “Home care agency” means any sole proprietorship,
20511350 partnership, association, corporation, or other organization which
20521351 administers, offers, or provides home care services, for a fee or
20531352 pursuant to a contract for such services, to clients in their place
20541353 of residence;
20551354 23. “Home care services” means skilled or personal care
20561355 services provided to clien ts in their place of residence fo r a fee;
20571356 24. “Hospice” means a centrally administered, nonprofit or for -
20581357 profit, medically directed, nurse -coordinated program which provides
2059-
2060-SENATE FLOOR VERSION - HB2584 SFLR Page 41
2061-(Bold face denotes Committee Amendments) 1
2062-2
2063-3
2064-4
2065-5
2066-6
2067-7
2068-8
2069-9
2070-10
2071-11
2072-12
2073-13
2074-14
2075-15
2076-16
2077-17
2078-18
2079-19
2080-20
2081-21
2082-22
2083-23
2084-24
2085-
20861358 a continuum of home and inpatient care for the terminally ill
20871359 patient and the patient’s family. Such term shall a lso include a
20881360 centrally administered, nonprofit or for -profit, medically directed,
20891361 nurse-coordinated program if such program is licensed pursuant to
20901362 the provisions of the Uniform Controlled Dangerous Substances Act.
1363+
1364+ENGR. H. B. NO. 2584 Page 28 1
1365+2
1366+3
1367+4
1368+5
1369+6
1370+7
1371+8
1372+9
1373+10
1374+11
1375+12
1376+13
1377+14
1378+15
1379+16
1380+17
1381+18
1382+19
1383+20
1384+21
1385+22
1386+23
1387+24
1388+
20911389 A hospice program offers palliative and supportive care to meet the
20921390 special needs arising out of the physical, emotional and spiritual
20931391 stresses which are experienced during the final stages of illness
20941392 and during dying and bereavement. This care is available twenty -
20951393 four (24) hours a day, seven (7) days a week, and is provided on the
20961394 basis of need, regardless of ability to pay. “Class A” Hospice
20971395 refers to Medicare-certified hospices. “Class B” refers to all
20981396 other providers of hospice services;
20991397 25. “Imitation controlled substance” means a subst ance that is
21001398 not a controlled dangerous substance, which by dosage unit
21011399 appearance, color, shape, size, markings or by representations made,
21021400 would lead a reasonable person to believe that the substance is a
21031401 controlled dangerous substance, or is a drug inte nded solely for
21041402 veterinary purposes that is not a controlled dangerous substance and
21051403 is being used outside of the scope of practice or normal course of
21061404 business, as defined by the State Board of Veterinary Medical
21071405 Examiners, or is a federal Food and Drug A dministration-approved
21081406 drug that is not a controlled dangerous substance and is being used
21091407 outside the scope of approval for illicit purposes such as
2110-
2111-SENATE FLOOR VERSION - HB2584 SFLR Page 42
2112-(Bold face denotes Committee Amendments) 1
2113-2
2114-3
2115-4
2116-5
2117-6
2118-7
2119-8
2120-9
2121-10
2122-11
2123-12
2124-13
2125-14
2126-15
2127-16
2128-17
2129-18
2130-19
2131-20
2132-21
2133-22
2134-23
2135-24
2136-
21371408 adulterating or lacing other controlled dangerous substances. In
21381409 the event the appearance of the dosage u nit or use is not reasonably
21391410 sufficient to establish that the substance is an imitation
21401411 controlled substance, the court or authority concerned should
21411412 consider, in addition to all other factors, the following factors:
1413+
1414+ENGR. H. B. NO. 2584 Page 29 1
1415+2
1416+3
1417+4
1418+5
1419+6
1420+7
1421+8
1422+9
1423+10
1424+11
1425+12
1426+13
1427+14
1428+15
1429+16
1430+17
1431+18
1432+19
1433+20
1434+21
1435+22
1436+23
1437+24
1438+
21421439 a. statements made by an owner or by an y other person in
21431440 control of the substance concerning the nature of the
21441441 substance, or its use or effect,
21451442 b. statements made to the recipient that the substance
21461443 may be resold for inordinate profit,
21471444 c. whether the substance is packaged in a manner normally
21481445 used for illicit controlled substances,
21491446 d. evasive tactics or actions utilized by the owner or
21501447 person in control of the substance to avoid detection
21511448 by law enforcement authorities,
21521449 e. prior convictions, if any, of an owner, or any other
21531450 person in control of the object, under state or
21541451 federal law related to controlled substances or fraud,
21551452 and
21561453 f. the proximity of the substances to controlled
21571454 dangerous substances;
21581455 26. “Immediate precursor” means a substance which the Director
21591456 has found to be and by regulation designates as being the principal
21601457 compound commonly used or produced primarily for use, and which is
2161-
2162-SENATE FLOOR VERSION - HB2584 SFLR Page 43
2163-(Bold face denotes Committee Amendments) 1
2164-2
2165-3
2166-4
2167-5
2168-6
2169-7
2170-8
2171-9
2172-10
2173-11
2174-12
2175-13
2176-14
2177-15
2178-16
2179-17
2180-18
2181-19
2182-20
2183-21
2184-22
2185-23
2186-24
2187-
21881458 an immediate chemical intermediary used, or likely to be used, in
21891459 the manufacture of a controlled dangerous substance, the control of
21901460 which is necessary to prevent, curtail or limit such manufacture;
21911461 27. “Initial prescription” means a prescription issued to a
21921462 patient who:
1463+
1464+ENGR. H. B. NO. 2584 Page 30 1
1465+2
1466+3
1467+4
1468+5
1469+6
1470+7
1471+8
1472+9
1473+10
1474+11
1475+12
1476+13
1477+14
1478+15
1479+16
1480+17
1481+18
1482+19
1483+20
1484+21
1485+22
1486+23
1487+24
1488+
21931489 a. has never previously been issued a prescription for
21941490 the drug or its pharmaceutical equivalent in the past
21951491 year, or
21961492 b. requires a prescription for the drug or its
21971493 pharmaceutical equivalent due to a surgical procedure
21981494 or new acute event and has previously had a
21991495 prescription for the drug or its pharmaceutical
22001496 equivalent within the past year.
22011497 When determining whether a patient was previously issued a
22021498 prescription for a drug or its pharmaceutical equivalent, the
22031499 practitioner shall consult with the patient and review the medical
22041500 record and prescription monitoring information of the patient;
22051501 28. “Isomer” means the optical isomer, except as used in
22061502 subsections C and F of Section 2 -204 of this title and paragraph 4
22071503 of subsection A of Section 2 -206 of this title. As used in
22081504 subsections C and F of Section 2 -204 of this title, isomer means the
22091505 optical, positional, or geometric isomer. As used in pa ragraph 4 of
22101506 subsection A of Section 2 -206 of this title, the term isomer means
22111507 the optical or geometric isomer;
2212-
2213-SENATE FLOOR VERSION - HB2584 SFLR Page 44
2214-(Bold face denotes Committee Amendments) 1
2215-2
2216-3
2217-4
2218-5
2219-6
2220-7
2221-8
2222-9
2223-10
2224-11
2225-12
2226-13
2227-14
2228-15
2229-16
2230-17
2231-18
2232-19
2233-20
2234-21
2235-22
2236-23
2237-24
2238-
22391508 29. “Laboratory” means a laboratory approved by the Director as
22401509 proper to be entrusted with the custody of controlled dangerous
22411510 substances and the use of controlled dangerous substances for
22421511 scientific and medical purposes and for purposes of instruction;
1512+
1513+ENGR. H. B. NO. 2584 Page 31 1
1514+2
1515+3
1516+4
1517+5
1518+6
1519+7
1520+8
1521+9
1522+10
1523+11
1524+12
1525+13
1526+14
1527+15
1528+16
1529+17
1530+18
1531+19
1532+20
1533+21
1534+22
1535+23
1536+24
1537+
22431538 30. “Manufacture” means the production, preparation,
22441539 propagation, compounding or processing of a controlled d angerous
22451540 substance, either direct ly or indirectly by extraction from
22461541 substances of natural or synthetic origin, or independently by means
22471542 of chemical synthesis or by a combination of extraction and chemical
22481543 synthesis. “Manufacturer” includes any person who packages,
22491544 repackages or labels any container of any controlled dangerous
22501545 substance, except practitioners who dispense or compound
22511546 prescription orders for delivery to the ultimate consumer;
22521547 31. “Marijuana” means all parts of the plant Cannabis sativa
22531548 L., whether growing or not; the seed s thereof; the resin extracted
22541549 from any part of such plant; and every compound, manufacture, salt,
22551550 derivative, mixture or preparation of such plant, its seeds or
22561551 resin, but shall not include:
22571552 a. the mature stalks of such plant or fiber produced from
22581553 such stalks,
22591554 b. oil or cake made from the seeds of such plant,
22601555 including cannabidiol derived from the seeds of the
22611556 marijuana plant,
2262-
2263-SENATE FLOOR VERSION - HB2584 SFLR Page 45
2264-(Bold face denotes Committee Amendments) 1
2265-2
2266-3
2267-4
2268-5
2269-6
2270-7
2271-8
2272-9
2273-10
2274-11
2275-12
2276-13
2277-14
2278-15
2279-16
2280-17
2281-18
2282-19
2283-20
2284-21
2285-22
2286-23
2287-24
2288-
22891557 c. any other compound, manufacture, salt, derivative,
22901558 mixture or preparation of such mature stalk s (except
22911559 the resin extracted the refrom), including cannabidiol
22921560 derived from mature stalks, fiber, oil or cake,
1561+
1562+ENGR. H. B. NO. 2584 Page 32 1
1563+2
1564+3
1565+4
1566+5
1567+6
1568+7
1569+8
1570+9
1571+10
1572+11
1573+12
1574+13
1575+14
1576+15
1577+16
1578+17
1579+18
1580+19
1581+20
1582+21
1583+22
1584+23
1585+24
1586+
22931587 d. the sterilized seed of such plant which is incapable
22941588 of germination,
22951589 e. for any person participating in a clinical trial to
22961590 administer cannabidiol for the treatment of severe
22971591 forms of epilepsy pursuant to Section 2 -802 of this
22981592 title, a drug or substance approved by the federal
22991593 Food and Drug Administration for use by those
23001594 participants,
23011595 f. for any person or the parents, legal guardians or
23021596 caretakers of the person who have recei ved a written
23031597 certification from a physician licensed in this state
23041598 that the person has been diagnosed by a physician as
23051599 having Lennox-Gastaut syndrome, Dravet syndrome, also
23061600 known as severe myoclonic epilepsy of infancy, or any
23071601 other severe form of epilep sy that is not adequately
23081602 treated by traditional medical therapies, spasticity
23091603 due to multiple sclerosis or due to paraplegia,
23101604 intractable nausea and vomiting, appetite stimulation
23111605 with chronic wasting diseases, the substan ce
23121606 cannabidiol, a nonpsychoactive cannabinoid, found in
2313-
2314-SENATE FLOOR VERSION - HB2584 SFLR Page 46
2315-(Bold face denotes Committee Amendments) 1
2316-2
2317-3
2318-4
2319-5
2320-6
2321-7
2322-8
2323-9
2324-10
2325-11
2326-12
2327-13
2328-14
2329-15
2330-16
2331-17
2332-18
2333-19
2334-20
2335-21
2336-22
2337-23
2338-24
2339-
23401607 the plant Cannabis sativa L. or any other preparation
23411608 thereof, that has a tetrahydrocannabinol concentration
23421609 not more than three-tenths of one percent (0.3%) and
1610+
1611+ENGR. H. B. NO. 2584 Page 33 1
1612+2
1613+3
1614+4
1615+5
1616+6
1617+7
1618+8
1619+9
1620+10
1621+11
1622+12
1623+13
1624+14
1625+15
1626+16
1627+17
1628+18
1629+19
1630+20
1631+21
1632+22
1633+23
1634+24
1635+
23431636 that is delivered to the patient in the form of a
23441637 liquid,
23451638 g. any federal Food and Drug Administration -approved drug
23461639 or substance, or
23471640 h. industrial hemp, from the plant Cannabis sativa L. and
23481641 any part of such plant, whether growing or not, with a
23491642 delta-9 tetrahydrocannabinol concentration not m ore
23501643 than three-tenths of one percent (0.3%) on a dry-
23511644 weight basis which shall only be grown pursuant to the
23521645 Oklahoma Industrial Hemp Program and may be shipped
23531646 intrastate and interstate;
23541647 32. “Medical purpose” means an intention to utilize a
23551648 controlled dangerous substance for physical or mental treatment, for
23561649 diagnosis, or for the prevention of a disease condition not in
23571650 violation of any state or federal law and not for the purpose of
23581651 satisfying physiological or psychological dependence or other abuse;
23591652 33. “Mid-level practitioner” means a n Advanced Practice
23601653 Registered Nurse as defined and within parameters specified in
23611654 Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified
23621655 animal euthanasia technician as defined in Section 698.2 of Title 59
23631656 of the Oklahoma Statutes, or an anim al control officer registered by
2364-
2365-SENATE FLOOR VERSION - HB2584 SFLR Page 47
2366-(Bold face denotes Committee Amendments) 1
2367-2
2368-3
2369-4
2370-5
2371-6
2372-7
2373-8
2374-9
2375-10
2376-11
2377-12
2378-13
2379-14
2380-15
2381-16
2382-17
2383-18
2384-19
2385-20
2386-21
2387-22
2388-23
2389-24
2390-
23911657 the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control
23921658 under subsection B of Section 2 -301 of this title within the
1659+
1660+ENGR. H. B. NO. 2584 Page 34 1
1661+2
1662+3
1663+4
1664+5
1665+6
1666+7
1667+8
1668+9
1669+10
1670+11
1671+12
1672+13
1673+14
1674+15
1675+16
1676+17
1677+18
1678+19
1679+20
1680+21
1681+22
1682+23
1683+24
1684+
23931685 parameters of such officer’s duties under Sections 501 through 508
23941686 of Title 4 of the Oklahoma S tatutes;
23951687 34. “Narcotic drug” means any of the following, whether
23961688 produced directly or indirectly by extraction from substances of
23971689 vegetable origin, or independently by means of chemical synthesis,
23981690 or by a combination of extraction and chemical synthesis:
23991691 a. opium, coca leaves and opiates,
24001692 b. a compound, manufacture, salt, derivative or
24011693 preparation of opium, coca leaves or opiates,
24021694 c. cocaine, its salts, optical and geometric isomers, and
24031695 salts of isomers,
24041696 d. ecgonine, its derivatives, their salts, isomers and
24051697 salts of isomers, and
24061698 e. a substance, and any compound, manufacture, salt,
24071699 derivative or preparation thereof, which is chemically
24081700 identical with any of the substances referred to in
24091701 subparagraphs a through d of this paragraph, except
24101702 that the words narcotic drug as used in Section 2 -101
24111703 et seq. of this title shall not include decocainized
24121704 coca leaves or extracts of coca leaves, which extracts
24131705 do not contain cocaine or ecgonine;
2414-
2415-SENATE FLOOR VERSION - HB2584 SFLR Page 48
2416-(Bold face denotes Committee Amendments) 1
2417-2
2418-3
2419-4
2420-5
2421-6
2422-7
2423-8
2424-9
2425-10
2426-11
2427-12
2428-13
2429-14
2430-15
2431-16
2432-17
2433-18
2434-19
2435-20
2436-21
2437-22
2438-23
2439-24
2440-
24411706 35. “Opiate” or “opioid” means any Schedul e II, III, IV or V
24421707 substance having an addiction-forming or addiction -sustaining
24431708 liability similar to morphine or being capable of conversion into a
1709+
1710+ENGR. H. B. NO. 2584 Page 35 1
1711+2
1712+3
1713+4
1714+5
1715+6
1716+7
1717+8
1718+9
1719+10
1720+11
1721+12
1722+13
1723+14
1724+15
1725+16
1726+17
1727+18
1728+19
1729+20
1730+21
1731+22
1732+23
1733+24
1734+
24441735 drug having such addiction -forming or addiction -sustaining
24451736 liability. The terms do not include, unless specifically designated
24461737 as controlled under the Uniform Controlled Dangerous Substances Act,
24471738 the dextrorotatory isomer of 3 -methoxy-n-methyl-morphinan and its
24481739 salts (dextromethorphan). The terms do include the racemic and
24491740 levorotatory forms;
24501741 36. “Opium poppy” means the plant of the species Papaver
24511742 somniferum L., except the seeds thereof;
24521743 37. “Palliative care” means a specialized medical service for
24531744 people of any age and at any stage of a serious illness or life -
24541745 altering medical event that focuses on navigating complex medical
24551746 decisions while providing patient autonomy and access to
24561747 information. Utilizing a holistic and interdisciplinary team
24571748 approach, palliative care addresses physical, intellectual,
24581749 emotional, social, and spiritual needs. Palliative care may be
24591750 provided in the inpatient, outpatient, or home care setting and
24601751 strives to improve quality of life for both the patient and the
24611752 family;
24621753 38. “Patient-provider agreement” means a written contract or
24631754 agreement that is executed between a practitioner and a patient
2464-
2465-SENATE FLOOR VERSION - HB2584 SFLR Page 49
2466-(Bold face denotes Committee Amendments) 1
2467-2
2468-3
2469-4
2470-5
2471-6
2472-7
2473-8
2474-9
2475-10
2476-11
2477-12
2478-13
2479-14
2480-15
2481-16
2482-17
2483-18
2484-19
2485-20
2486-21
2487-22
2488-23
2489-24
2490-
24911755 prior to the commenc ement of treatment for chronic pain using an
24921756 opioid drug as a means to:
1757+
1758+ENGR. H. B. NO. 2584 Page 36 1
1759+2
1760+3
1761+4
1762+5
1763+6
1764+7
1765+8
1766+9
1767+10
1768+11
1769+12
1770+13
1771+14
1772+15
1773+16
1774+17
1775+18
1776+19
1777+20
1778+21
1779+22
1780+23
1781+24
1782+
24931783 a. explain the possible risk of development of physical
24941784 or psychological dependence in the patient and prevent
24951785 the possible development of addiction,
24961786 b. document the understanding of b oth the practitioner
24971787 and the patient regarding the patient -provider
24981788 agreement of the patient,
24991789 c. establish the rights of the patient in association
25001790 with treatment and the obligations of the patient in
25011791 relation to the responsible use, discontinuation of
25021792 use, and storage of opioid drugs, including any
25031793 restrictions on the refill of prescriptions or the
25041794 acceptance of opioid prescriptions from practitioners,
25051795 d. identify the specific medications and other modes of
25061796 treatment, including physical therapy or exercise ,
25071797 relaxation, or psychological counseling, that are
25081798 included as a part of the patient -provider agreement,
25091799 e. specify the measures the practitioner may employ to
25101800 monitor the compliance of the patient including, but
25111801 not limited to, random specimen screens an d pill
25121802 counts, and
25131803 f. delineate the process for terminating the agreement,
25141804 including the consequences if the practitioner has
2515-
2516-SENATE FLOOR VERSION - HB2584 SFLR Page 50
2517-(Bold face denotes Committee Amendments) 1
2518-2
2519-3
2520-4
2521-5
2522-6
2523-7
2524-8
2525-9
2526-10
2527-11
2528-12
2529-13
2530-14
2531-15
2532-16
2533-17
2534-18
2535-19
2536-20
2537-21
2538-22
2539-23
2540-24
2541-
25421805 reason to believe that the patient is not complying
25431806 with the terms of the agreement. Compliance with the
1807+
1808+ENGR. H. B. NO. 2584 Page 37 1
1809+2
1810+3
1811+4
1812+5
1813+6
1814+7
1815+8
1816+9
1817+10
1818+11
1819+12
1820+13
1821+14
1822+15
1823+16
1824+17
1825+18
1826+19
1827+20
1828+21
1829+22
1830+23
1831+24
1832+
25441833 consent items described in this paragraph shall
25451834 constitute a valid, informed consent for opioid
25461835 therapy. The practitioner shall be held harmless from
25471836 civil litigation for failure to treat pain if the
25481837 event occurs because of nonadherence by the patient
25491838 with any of the provisions of the patient-provider
25501839 agreement;
25511840 39. “Peace officer” means a police officer, sheriff, deputy
25521841 sheriff, district attorney’s investigator, investigator from the
25531842 Office of the Attorney General, or any other person elected or
25541843 appointed by law to enforce any of the criminal laws of this state
25551844 or of the United States;
25561845 40. “Person” means an individual, corporation, government or
25571846 governmental subdivision or agency, business trust, estate, trust,
25581847 partnership or association, or any other legal entity;
25591848 41. “Poppy straw” means all parts, except the seeds, of the
25601849 opium poppy, after mowing;
25611850 42. “Practitioner” means:
25621851 a. (1) a medical doctor or osteopathic physician,
25631852 (2) a dentist,
25641853 (3) a podiatrist,
25651854 (4) an optometrist,
2566-
2567-SENATE FLOOR VERSION - HB2584 SFLR Page 51
2568-(Bold face denotes Committee Amendments) 1
2569-2
2570-3
2571-4
2572-5
2573-6
2574-7
2575-8
2576-9
2577-10
2578-11
2579-12
2580-13
2581-14
2582-15
2583-16
2584-17
2585-18
2586-19
2587-20
2588-21
2589-22
2590-23
2591-24
2592-
25931855 (5) a veterinarian,
1856+
1857+ENGR. H. B. NO. 2584 Page 38 1
1858+2
1859+3
1860+4
1861+5
1862+6
1863+7
1864+8
1865+9
1866+10
1867+11
1868+12
1869+13
1870+14
1871+15
1872+16
1873+17
1874+18
1875+19
1876+20
1877+21
1878+22
1879+23
1880+24
1881+
25941882 (6) a physician assistant or an Advanced Practice
25951883 Registered Nurse under the supervision of a
25961884 licensed medical doctor or osteopathic physician ,
25971885 or a physician assistant ,
25981886 (7) a scientific investigator, or
25991887 (8) any other person,
26001888 licensed, registered or otherwise permitted to
26011889 prescribe, distribute, dispense, conduct research with
26021890 respect to, use for scientific purposes or administer
26031891 a controlled dangerous substance in the course of
26041892 professional practice or research in this state, or
26051893 b. a pharmacy, hospital, laboratory or other institution
26061894 licensed, registered or otherwise permitted to
26071895 distribute, dispense, conduct research with respect
26081896 to, use for scientific purposes or administer a
26091897 controlled dangerous substance in the course of
26101898 professional practice or research in this state;
26111899 43. “Production” includes the manufacture, planting,
26121900 cultivation, growing or harvesting of a controlled dangerous
26131901 substance;
26141902 44. “Serious illness” means a medical illness or physical
26151903 injury or condition that substantially affects qual ity of life for
26161904 more than a short period of time. Serious illness includes, but is
2617-
2618-SENATE FLOOR VERSION - HB2584 SFLR Page 52
2619-(Bold face denotes Committee Amendments) 1
2620-2
2621-3
2622-4
2623-5
2624-6
2625-7
2626-8
2627-9
2628-10
2629-11
2630-12
2631-13
2632-14
2633-15
2634-16
2635-17
2636-18
2637-19
2638-20
2639-21
2640-22
2641-23
2642-24
2643-
26441905 not limited to, Alzheimer’s disease or related dementias, lung
1906+
1907+ENGR. H. B. NO. 2584 Page 39 1
1908+2
1909+3
1910+4
1911+5
1912+6
1913+7
1914+8
1915+9
1916+10
1917+11
1918+12
1919+13
1920+14
1921+15
1922+16
1923+17
1924+18
1925+19
1926+20
1927+21
1928+22
1929+23
1930+24
1931+
26451932 disease, cancer, heart failure, renal failure, liver failure, or
26461933 chronic, unremitting, or intractable pain such as neuropathic pain;
26471934 45. “State” means the State of Oklahoma or any other state of
26481935 the United States;
26491936 46. “Straw person” or “straw party”, also known as a “front”,
26501937 means a third party who:
26511938 a. is put up in name only to take part in a transaction
26521939 or otherwise is a nominal party to a tr ansaction with
26531940 no actual control,
26541941 b. acts on behalf of another person to obtain title to
26551942 property and executes documents and instruments the
26561943 principal may direct respecting property, or
26571944 c. purchases property for another for the purpose of
26581945 concealing the identity of the real purchaser or to
26591946 accomplish some purpose otherwise in violation of the
26601947 Oklahoma Statutes;
26611948 47. “Surgical procedure” means a procedure that is performed
26621949 for the purpose of structurally altering the human bo dy by incision
26631950 or destruction of tissues as part of the practice of medicine. This
26641951 term includes the diagnostic or therapeutic treatment of conditions
26651952 or disease processes by use of instruments such as lasers,
26661953 ultrasound, ionizing, radiation, scalpels, probes, or needles that
26671954 cause localized alteration or transportation of live human tissue by
2668-
2669-SENATE FLOOR VERSION - HB2584 SFLR Page 53
2670-(Bold face denotes Committee Amendments) 1
2671-2
2672-3
2673-4
2674-5
2675-6
2676-7
2677-8
2678-9
2679-10
2680-11
2681-12
2682-13
2683-14
2684-15
2685-16
2686-17
2687-18
2688-19
2689-20
2690-21
2691-22
2692-23
2693-24
2694-
26951955 cutting, burning, vaporizing, freezing, suturing, probing, or
1956+
1957+ENGR. H. B. NO. 2584 Page 40 1
1958+2
1959+3
1960+4
1961+5
1962+6
1963+7
1964+8
1965+9
1966+10
1967+11
1968+12
1969+13
1970+14
1971+15
1972+16
1973+17
1974+18
1975+19
1976+20
1977+21
1978+22
1979+23
1980+24
1981+
26961982 manipulating by closed reduction for major dislocations or
26971983 fractures, or otherwise altering by any mech anical, thermal, light -
26981984 based, electromagnetic, or chemical means;
26991985 48. a. “Synthetic controlled substance” means a substance:
27001986 (1) the chemical structure of which is substantially
27011987 similar to the chemical structure of a controlled
27021988 dangerous substance in Schedule I or II,
27031989 (2) which has a stimulant, depressant, or
27041990 hallucinogenic effect on the central nervous
27051991 system that is substantially similar to or
27061992 greater than the stimulant, depressant, or
27071993 hallucinogenic effect on the central nervous
27081994 system of a controlled da ngerous substance in
27091995 Schedule I or II, or
27101996 (3) with respect to a particular person, which such
27111997 person represents or intends to have a stimulant,
27121998 depressant, or hallucinogenic effect on the
27131999 central nervous system that is substantially
27142000 similar to or greater than the stimulant,
27152001 depressant, or hallucinogenic effect on the
27162002 central nervous system of a controlled dangerous
27172003 substance in Schedule I or II.
2718-
2719-SENATE FLOOR VERSION - HB2584 SFLR Page 54
2720-(Bold face denotes Committee Amendments) 1
2721-2
2722-3
2723-4
2724-5
2725-6
2726-7
2727-8
2728-9
2729-10
2730-11
2731-12
2732-13
2733-14
2734-15
2735-16
2736-17
2737-18
2738-19
2739-20
2740-21
2741-22
2742-23
2743-24
2744-
27452004 b. The designation of gamma -butyrolactone or any other
27462005 chemical as a precursor, pursuant to Section 2 -322 of
2006+
2007+ENGR. H. B. NO. 2584 Page 41 1
2008+2
2009+3
2010+4
2011+5
2012+6
2013+7
2014+8
2015+9
2016+10
2017+11
2018+12
2019+13
2020+14
2021+15
2022+16
2023+17
2024+18
2025+19
2026+20
2027+21
2028+22
2029+23
2030+24
2031+
27472032 this title, does not preclude a findi ng pursuant to
27482033 subparagraph a of this paragraph that the chemical is
27492034 a synthetic controlled substance.
27502035 c. Synthetic controlled substance does not include:
27512036 (1) a controlled dangerous substance,
27522037 (2) any substance for which there is an approved new
27532038 drug application,
27542039 (3) with respect to a particular person any
27552040 substance, if an exemption is in effect for
27562041 investigational use, for that person under the
27572042 provisions of Section 505 of the Federal Food,
27582043 Drug, and Cosmetic Act, 21 U.S.C. , Section 355,
27592044 to the extent conduct with respect to such
27602045 substance is pursuant to such exemption, or
27612046 (4) any substance to the extent not intended for
27622047 human consumption before such an exemption takes
27632048 effect with respect to that substance.
27642049 d. Prima facie evidence that a substance containin g
27652050 salvia divinorum has been enhanced, concentrated, or
27662051 chemically or physically altered shall give rise to a
27672052 rebuttable presumption that the substance is a
27682053 synthetic controlled substance;
2769-
2770-SENATE FLOOR VERSION - HB2584 SFLR Page 55
2771-(Bold face denotes Committee Amendments) 1
2772-2
2773-3
2774-4
2775-5
2776-6
2777-7
2778-8
2779-9
2780-10
2781-11
2782-12
2783-13
2784-14
2785-15
2786-16
2787-17
2788-18
2789-19
2790-20
2791-21
2792-22
2793-23
2794-24
2795-
27962054 49. “Tetrahydrocannabinols” means all substances that have been
27972055 chemically synthesized to emulate the tetrahydrocannabinols of
2056+
2057+ENGR. H. B. NO. 2584 Page 42 1
2058+2
2059+3
2060+4
2061+5
2062+6
2063+7
2064+8
2065+9
2066+10
2067+11
2068+12
2069+13
2070+14
2071+15
2072+16
2073+17
2074+18
2075+19
2076+20
2077+21
2078+22
2079+23
2080+24
2081+
27982082 marijuana, specifically including any tetrahydrocannabinols derived
27992083 from industrial hemp; and
28002084 50. “Ultimate user” means a person who lawfully possesses a
28012085 controlled dangerous substance for the pe rson’s own use or for the
28022086 use of a member of the person’s household or for administration to
28032087 an animal owned by the person or by a member of the person’s
28042088 household.
2805-SECTION 9. AMENDATORY 63 O.S. 2021, Section 2 -312, as
2089+SECTION 8. AMENDATORY 63 O.S. 20 21, Section 2-312, as
28062090 amended by Section 2, Chapter 184, O.S.L. 2022 (63 O.S. Supp. 2024,
28072091 Section 2-312), is amended to read as follows:
28082092 Section 2-312. A. A physician, podiatrist, optometrist or a
28092093 dentist who has complied with the registration requirements of the
28102094 Uniform Controlled Dang erous Substances Act, in good faith and in
28112095 the course of such person's professional practice only, may
28122096 prescribe and administer controlled dangerous substances, or may
28132097 cause the same to be administered by medical or paramed ical
28142098 personnel acting under the d irection and supervision of the
28152099 physician, podiatrist, optometrist or dentist, and only may dispense
28162100 controlled dangerous substances pursuant to the provisions of
28172101 Sections 355.1 and 355.2 of Title 59 of the Oklahoma Statutes.
28182102 B. A veterinarian who has com plied with the registration
28192103 requirements of the Uniform Controlled Dangerous Substances Act, in
2820-
2821-SENATE FLOOR VERSION - HB2584 SFLR Page 56
2822-(Bold face denotes Committee Amendments) 1
2823-2
2824-3
2825-4
2826-5
2827-6
2828-7
2829-8
2830-9
2831-10
2832-11
2833-12
2834-13
2835-14
2836-15
2837-16
2838-17
2839-18
2840-19
2841-20
2842-21
2843-22
2844-23
2845-24
2846-
28472104 good faith and in the course of the professional practice of the
28482105 veterinarian only, and not for use by a human being, may presc ribe,
2106+
2107+ENGR. H. B. NO. 2584 Page 43 1
2108+2
2109+3
2110+4
2111+5
2112+6
2113+7
2114+8
2115+9
2116+10
2117+11
2118+12
2119+13
2120+14
2121+15
2122+16
2123+17
2124+18
2125+19
2126+20
2127+21
2128+22
2129+23
2130+24
2131+
28492132 administer, and dispense co ntrolled dangerous substances and may
28502133 cause them to be administered by an assistant or orderly under the
28512134 direction and supervision of the veterinarian.
28522135 C. An advanced practice nurse who is recognized to prescribe by
28532136 the Oklahoma Board of Nursing as an adv anced registered nurse
28542137 practitioner, clinical nurse specialist or certified nurse -midwife,
28552138 who is subject to medical direction by a supervising physician,
28562139 pursuant to Section 567.3a of Title 59 of the Oklahoma Statutes, and
28572140 who has complied with the regist ration requirements of the Uniform
28582141 Controlled Dangerous Substances Act, in good faith and in the course
28592142 of professional practice only, may prescribe and administer Schedule
28602143 III, IV and V controlled dangerous substances.
28612144 D. An advanced practice nurse who i s recognized to order,
28622145 select, obtain and administer drugs by the Oklahoma Board of Nursing
28632146 as a certified registered nurse anesthetist pursuant to Section
28642147 353.1b of Title 59 of the Oklahoma Statutes and who has complied
28652148 with the registration requirements of the Uniform Controlled
28662149 Dangerous Substances Act, in good faith and in the course of such
28672150 practitioner's professional practice only, may order, select, obtain
28682151 and administer Schedules II through V controlled dangerous
28692152 substances in a preanesthetic prepar ation or evaluation; anesthesia
28702153 induction, maintenance or emergence; or postanesthesia care setting
2871-
2872-SENATE FLOOR VERSION - HB2584 SFLR Page 57
2873-(Bold face denotes Committee Amendments) 1
2874-2
2875-3
2876-4
2877-5
2878-6
2879-7
2880-8
2881-9
2882-10
2883-11
2884-12
2885-13
2886-14
2887-15
2888-16
2889-17
2890-18
2891-19
2892-20
2893-21
2894-22
2895-23
2896-24
2897-
28982154 only. A certified registered nurse anesthetist may order, select,
2155+
2156+ENGR. H. B. NO. 2584 Page 44 1
2157+2
2158+3
2159+4
2160+5
2161+6
2162+7
2163+8
2164+9
2165+10
2166+11
2167+12
2168+13
2169+14
2170+15
2171+16
2172+17
2173+18
2174+19
2175+20
2176+21
2177+22
2178+23
2179+24
2180+
28992181 obtain and administer such drugs only during the periope rative or
29002182 periobstetrical period.
29012183 E. A physician assistant who is recognized to prescribe by the
29022184 State Board of Medical Licensure and Supervision under the medical
29032185 direction of a supervising physician, pursuant to Section 519.6 of
29042186 Title 59 of the Oklahoma Statutes, and who has complied w ith the
29052187 registration requirements of the Uniform Controlled Dangerous
29062188 Substances Act, in good faith and in the course of professional
29072189 practice only, may prescribe and administer Schedule II through V
29082190 controlled dangerous su bstances subject to the restricti ons in
29092191 Section 519.6 of Title 59 of the Oklahoma Statutes .
2910-SECTION 10. REPEALER 59 O.S. 2021, Section 521.4, is
2192+SECTION 9. REPEALER 59 O.S. 2021, Section 521.4, is
29112193 hereby repealed.
2912-COMMITTEE REPORT BY: COMMITTEE ON HEALTH AND HUMAN SERVICES
2913-April 21, 2025 - DO PASS AS AMENDED
2194+Passed the House of Representatives the 25th day of March, 2025.
2195+
2196+
2197+
2198+
2199+ Presiding Officer of the House
2200+ of Representatives
2201+
2202+
2203+
2204+Passed the Senate the ____ day of __________, 2025.
2205+
2206+
2207+
2208+
2209+ Presiding Officer of the Senate
2210+
2211+
2212+
2213+